Pharmaceutical composition comprising Anti-GIPR antibody or antigen-binding fragment thereof, and use
By combining anti-GIPR antibodies and GLP-1/GCG dual receptor agonists, the limited efficacy of monotherapy in obesity treatment has been addressed, achieving synergistic treatment and management of obesity and related diseases.
Patent Information
- Application Number
- PCT/CN2026/096935
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-11-14
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Existing single-drug therapies have limited efficacy in treating obesity and cannot effectively prevent or alleviate a variety of health problems caused by obesity, particularly type 2 diabetes, heart disease, obstructive sleep apnea, non-alcoholic fatty liver disease, and cancer.
Combining anti-GIPR antibodies or their antigen-binding fragments with GLP-1/GCG dual receptor agonists or their pharmaceutically acceptable salts, via subcutaneous or simultaneous injection, can synergistically reduce weight, improve liver function, and regulate blood glucose.
It achieves synergistic therapeutic effects on obesity and related diseases, reducing weight, improving liver function, lowering ALT levels, effectively regulating blood sugar, and reducing related health risks.
Smart Images

Figure CN2026096935_19112026_PF_FP_ABST
Abstract
Description
Pharmaceutical compositions comprising anti-GIPR antibodies or their antigen-binding fragments and their uses Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to pharmaceutical compositions and uses comprising anti-GIPR antibodies or their antigen-binding fragments. Background Technology
[0002] Glucose-dependent insulinotropic peptide (GIP, also known as gastric inhibitory peptide) and glucagon-like peptide-1 (GLP-1) are two important endogenous incretins involved in the regulation of energy homeostasis, including glucose and lipid metabolism, appetite, and body weight. GIP, composed of 42 amino acids, is released from K cells in the intestine after food intake. GIP participates in the physiological process of stimulating insulin secretion by activating the enteroincreased-gastric peptide receptor (GIPR) on the surface of pancreatic β cells, influencing adipocyte lipid synthesis, and regulating satiety.
[0003] The GIP receptor (GIPR) is crucial for GIP to function. Specifically, GIP binding to GIPR causes a conformational change in G proteins, activates adenylate cyclase, releases cAMP, increases intracellular cAMP concentration, and activates the PAK signaling pathway. This, in turn, increases the phosphorylation of key proteins controlling insulin synthesis and secretion (such as CREB), ultimately promoting insulin secretion after glucose stimulation. GIP needs to bind to its corresponding GIPR on the cell surface to exert its biological effects.
[0004] Glucagon-like peptide-1 (GLP-1) is primarily secreted by intestinal L cells, with GLP-1(7-36) being its main active form. GLP-1 exerts its effects by binding to the GLP-1 receptor (GLP-1R), promoting insulin secretion from pancreatic β cells, delaying gastric emptying, reducing postprandial blood glucose fluctuations, increasing satiety, reducing food intake, and lowering the risk of cardiovascular disease. Glucagon (GCG) is a polypeptide hormone secreted by pancreatic α cells, primarily functioning in hypoglycemic states by promoting glycogenolysis and gluconeogenesis to raise blood glucose levels. GCG exerts its effects by binding to the glucagon receptor (GCGR), maintaining glycemic homeostasis in hypoglycemic states and influencing body weight by promoting lipolysis and increasing energy expenditure. The representative GLP-1 / GCG dual receptor agonist, Mazdutide, has been approved for marketing and has shown beneficial effects in the indications of obesity and overweight.
[0005] Obesity is associated with many serious health consequences and shortened life expectancy, including complications such as type 2 diabetes, heart disease, obstructive sleep apnea, non-alcoholic fatty liver disease, and cancer. Obesity has become a significant factor affecting public health; however, the efficacy of single-drug therapy is limited, thus creating an unmet clinical need in the treatment of obesity. Summary of the Invention
[0006] On the one hand, this article provides a drug combination comprising:
[0007] (a) an anti-GIPR antibody or its antigen-binding fragment; and,
[0008] (b) A GLP-1 / GCG dual receptor agonist or a pharmaceutically acceptable salt thereof, or a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof.
[0009] On the one hand, this article provides a pharmaceutical composition comprising:
[0010] (a) an anti-GIPR antibody or its antigen-binding fragment; and,
[0011] (b) A GLP-1 / GCG dual receptor agonist or a pharmaceutically acceptable salt thereof, or a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof.
[0012] On the one hand, this article provides a reagent kit or medicine box containing:
[0013] (a) an anti-GIPR antibody or its antigen-binding fragment; and,
[0014] (b) A GLP-1 / GCG dual receptor agonist or a pharmaceutically acceptable salt thereof, or a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof.
[0015] On the one hand, this article provides a method for preventing, alleviating and / or treating obesity or obesity-related diseases or conditions in subjects, comprising co-administering to subjects in need (a) an anti-GIPR antibody or an antigen-binding fragment thereof and (b) a GLP-1 / GCG dual receptor agonist or a pharmaceutically acceptable salt thereof or a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof.
[0016] On the one hand, this article provides a method for preventing, alleviating and / or treating obesity or obesity-related diseases or conditions in subjects, comprising administering the aforementioned combination of drugs, the aforementioned pharmaceutical composition, the aforementioned kit or cassette to subjects in need.
[0017] On the one hand, this article provides the use of (a) an anti-GIPR antibody or its antigen-binding fragment in combination with (b) a GLP-1 / GCG dual receptor agonist or a pharmaceutically acceptable salt thereof, or a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof, in the preparation of a medicine, a pharmaceutical composition, a kit or cassette.
[0018] In any of the embodiments of the foregoing aspects, the drug combination, drug, pharmaceutical composition, kit, or cassette is used to prevent, alleviate, and / or treat obesity or obesity-related diseases or conditions in a subject. In any of the embodiments of the foregoing aspects, the drug combination, drug, pharmaceutical composition, kit, or cassette is used for weight management or weight reduction. In any of the embodiments of the foregoing aspects, the drug combination, drug, pharmaceutical composition, kit, or cassette is used to improve liver function, reduce liver weight, or regulate blood glucose (e.g., lower blood glucose), such as lowering ALT levels.
[0019] In any of the embodiments of the foregoing aspects, the drug combination, drug, pharmaceutical composition, kit, or cassette has a synergistic effect on weight, weight management, or weight reduction. In any of the embodiments of the foregoing aspects, the drug combination, drug, pharmaceutical composition, kit, or cassette has a synergistic effect on improving liver function (e.g., lowering ALT levels).
[0020] In any of the above-mentioned implementations, each of (a) and (b) is present in an effective amount.
[0021] In any of the embodiments described above, the kit or medicine box optionally further includes a packaging insert containing instructions for using (a) in conjunction with (b) to treat obesity or obesity-related diseases or conditions in the subject.
[0022] In any of the embodiments described above, the pharmaceutical composition further includes one or more pharmaceutically acceptable excipients.
[0023] In any of the above embodiments, the kit or cassette may contain the aforementioned pharmaceutical composition, or may contain two single formulations of (a) and (b).
[0024] In any of the above embodiments, each of (a) and (b) further comprises one or more pharmaceutically acceptable excipients.
[0025] In embodiments of any of the foregoing aspects, excipients that may be used include carriers, surfactants, thickeners or emulsifiers, solid binders, dispersants or suspending agents, solubilizers, colorants, flavoring agents, coating agents, disintegrants, lubricants, sweeteners, preservatives, isotonic agents, or combinations thereof. The selection and use of appropriate excipients are taught in the following, Gennaro, ed., Remington: The Science and Practice of Pharmacy, 20th edition (Lippincott Williams & Wilkins 2003), the disclosure of which is incorporated herein by reference.
[0026] In any of the above-mentioned implementation schemes, diseases or conditions caused by obesity include, but are not limited to: diabetes, hypertension, insulin resistance, dyslipidemia, cardiovascular disease, cerebrovascular disease, metabolic syndrome, liver disease, fatty liver, non-alcoholic fatty liver, atherosclerosis, peripheral artery disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease and arrhythmia, type 2 diabetes, diabetic nephropathy, etc.
[0027] In any of the embodiments of the foregoing aspects, the drug combination, or the drug composition, or the kit, or the cassette, or (a) and (b) may be administered by a variety of methods known in the art.
[0028] In any of the above-mentioned implementations, co-administration may be performed simultaneously and / or sequentially in any order, for example: simultaneous administration of (a) and (b); administration of (b) prior to (a); administration of (a) prior to (b); administration of (a) separately for a period of time, followed by simultaneous administration of (a) and (b); administration of (b) separately for a period of time, followed by simultaneous administration of (a) and (b); administration of (b) separately for a period of time, followed by administration of (a) separately; administration of (a) separately for a period of time, followed by administration of (b) separately; or, simultaneous administration of (a) and (b) for a period of time, followed by administration of (a) separately. When (a) and (b) are administered co-administered, they may be administered in two separate administrations on the same day, for example, administration of one drug may be permitted within minutes, tens of minutes, or hours after administration of another drug, with the administration interval of (a) and (b) including but not limited to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, and 2 hours. When (a) and (b) are administered together, a significant time interval is allowed between the administration of one drug and the administration of the other, meaning that when the second drug is administered, the first drug may no longer be present in the subject at an effective level. Preferably, the co-administration allows for a period of time during which both drugs exert their biological activity simultaneously.
[0029] In any of the embodiments described above, the drug combination, pharmaceutical composition, kit, or cassette is preferably administered subcutaneously, or each of (a) and (b) is preferably administered subcutaneously. For example, (a) and (b) may be administered via two separate injections or via a single injection.
[0030] In any of the embodiments of the foregoing aspects, the dose (preferably unit dose) ratio, weight ratio, or molar ratio of (a) and (b) is in the range of 5:1 to 500:1, 5:1 to 400:1, 5:1 to 300:1, 5:1 to 200:1, 10:1 to 500:1, 10:1 to 400:1, 10:1 to 300:1, or 10:1 to 200:1, preferably 500:1, 200:1, 13:1 to 14:1, or 5:1 to 6:1.
[0031] In any of the above embodiments, (a) is present in a dose range of 100-1000 mg (preferably unit dose).
[0032] In any of the above embodiments, (b) is present in a dose range of 0.1-10 mg (preferably a unit dose), preferably 0.25 mg, 0.5 mg, 0.6 mg, 1.0 mg, 1.7 mg, 2.4 mg, 3.6 mg, 4.8 mg, or 6.0 mg.
[0033] In any of the above embodiments, (a) is applied once a week, every two weeks, every three weeks, every month, every two months, every three months, every four months, every five months, or every six months.
[0034] In any of the above embodiments, (b) is applied once daily, every three days, or weekly.
[0035] In any of the embodiments described above, the GLP-1 / GCG dual receptor agonist is present at a dose (preferably a unit dose) of 0.6 mg, 2.4 mg, 3.6 mg, 4.8 mg, or 6.0 mg, and / or the GLP-1 / GCG dual receptor agonist is administered once weekly. In some embodiments, the GLP-1 / GCG dual receptor agonist is administered once weekly at a dose of 4.8 mg (preferably a unit dose).
[0036] In any of the embodiments described above, the GLP-1 receptor agonist is present at a dose (preferably a unit dose) of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, or 2.4 mg, and / or the GLP-1 receptor agonist is administered once weekly. In some embodiments, the GLP-1 receptor agonist is administered once weekly at a dose not exceeding 2.4 mg (preferably a unit dose), for example, at a dose of 0.5 mg (preferably a unit dose) once weekly, at a dose of 1.0 mg (preferably a unit dose) once weekly, at a dose of 1.7 mg (preferably a unit dose) once weekly, or at a dose of 2.4 mg (preferably a unit dose) once weekly.
[0037] In any of the embodiments described above, the anti-GIPR antibody or its antigen-binding fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises HCDR1, HCDR2, and HCDR3 regions, and the VL comprises LCDR1, LCDR2, and LCDR3 regions, wherein:
[0038] (1) The HCDR1, HCDR2, and HCDR3 regions have sequences identical to those of the HCDR1, HCDR2, and HCDR3 of any VH shown in SEQ ID NO: 1, 3, 5, or 7, or sequences with at most 5, 4, 3, 2, or 1 mutations compared to each CDR in HCDR1-3 of any VH shown in SEQ ID NO: 1, 3, 5, or 7; and the LCDR1, LCDR2, and LCDR3 regions have sequences identical to those of the LCDR1, LCDR2, and LCDR3 of any VL shown in SEQ ID NO: 2, 4, 6, or 8, or sequences with at most 5, 4, 3, 2, or 1 mutations compared to each CDR in LCDR1-3 of any VL shown in SEQ ID NO: 2, 4, 6, or 8; or,
[0039] (2) The HCDR1, HCDR2, and HCDR3 regions have sequences identical to those of the HCDR1, HCDR2, and HCDR3 of any VH shown in SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, or sequences that have undergone at most 5, 4, 3, 2, or 1 mutations compared to each CDR in HCDR1-3 of any VH shown in SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and ... NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, each of the LCDR1-3 of any of the VLs shown has a sequence with up to 5, 4, 3, 2 or 1 mutations compared to the sequence.
[0040] In some implementations, the VH includes regions HCDR1, HCDR2, and HCDR3, and the VL includes regions LCDR1, LCDR2, and LCDR3, wherein:
[0041] (1) The HCDR1, HCDR2 and HCDR3 regions have the same sequence as HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO: 1, or have a sequence with up to 5, 4, 3, 2 or 1 mutations compared to each CDR in HCDR1-3 of VH as shown in SEQ ID NO: 1; and the LCDR1, LCDR2 and LCDR3 regions have the same sequence as LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO: 2, or have a sequence with up to 5, 4, 3, 2 or 1 mutations compared to each CDR in LCDR1-3 of VL as shown in SEQ ID NO: 2;
[0042] (2) The HCDR1, HCDR2, and HCDR3 regions have the same sequence as HCDR1, HCDR2, and HCDR3 of VH as shown in SEQ ID NO: 3, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in HCDR1-3 of VH as shown in SEQ ID NO: 3; and the LCDR1, LCDR2, and LCDR3 regions have the same sequence as LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO: 4, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in LCDR1-3 of VL as shown in SEQ ID NO: 4;
[0043] (3) The HCDR1, HCDR2, and HCDR3 regions have the same sequence as HCDR1, HCDR2, and HCDR3 of VH as shown in SEQ ID NO: 5, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in HCDR1-3 of VH as shown in SEQ ID NO: 5; and the LCDR1, LCDR2, and LCDR3 regions have the same sequence as LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO: 6, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in LCDR1-3 of VL as shown in SEQ ID NO: 6;
[0044] (4) The HCDR1, HCDR2, and HCDR3 regions have the same sequence as HCDR1, HCDR2, and HCDR3 of VH as shown in SEQ ID NO: 9, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in HCDR1-3 of VH as shown in SEQ ID NO: 9; and the LCDR1, LCDR2, and LCDR3 regions have the same sequence as LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO: 10, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in LCDR1-3 of VL as shown in SEQ ID NO: 10;
[0045] (5) The HCDR1, HCDR2, and HCDR3 regions have the same sequence as HCDR1, HCDR2, and HCDR3 of VH as shown in SEQ ID NO: 11, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in HCDR1-3 of VH as shown in SEQ ID NO: 11; and the LCDR1, LCDR2, and LCDR3 regions have the same sequence as LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO: 12, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in LCDR1-3 of VL as shown in SEQ ID NO: 12;
[0046] (6) The HCDR1, HCDR2, and HCDR3 regions have sequences identical to those of HCDR1, HCDR2, and HCDR3 of VH as shown in SEQ ID NO: 13, or sequences with at most 5, 4, 3, 2, or 1 mutation compared to each CDR in HCDR1-3 of VH as shown in SEQ ID NO: 13; and the LCDR1, LCDR2, and LCDR3 regions have sequences identical to those of LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO: 14, or sequences with at most 5, 4, 3, 2, or 1 mutation compared to each CDR in LCDR1-3 of VL as shown in SEQ ID NO: 14; or
[0047] (7) The HCDR1, HCDR2, and HCDR3 regions have the same sequence as HCDR1, HCDR2, and HCDR3 of VH as shown in SEQ ID NO: 31, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in HCDR1-3 of VH as shown in SEQ ID NO: 31; and the LCDR1, LCDR2, and LCDR3 regions have the same sequence as LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO: 32, or have a sequence with up to 5, 4, 3, 2, or 1 mutation compared to each CDR in LCDR1-3 of VL as shown in SEQ ID NO: 32;
[0048] The mutation is selected from insertions, deletions and / or substitutions that do not affect function, and the substitution is preferably a substitution of a conserved amino acid.
[0049] In any of the embodiments described above, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 1, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 2. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 3, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 4. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 5, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 6. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 7, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 8. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 9, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 10. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 11, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 12. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 13, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 14. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 15, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 16. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 17, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 18.In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 19, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 20. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 21, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 22. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 23, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 24. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 25, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 26. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 27, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 28. In some embodiments, the VH has the same sequences HCDR1, HCDR2, and HCDR3 as the VH shown in SEQ ID NO: 29, and the VL has the same sequences LCDR1, LCDR2, and LCDR3 as the VL shown in SEQ ID NO: 30. In some embodiments, the VH has the same sequence HCDR1, HCDR2 and HCDR3 as the VH shown in SEQ ID NO: 31, and the VL has the same sequence LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO: 32.
[0050] In any of the above embodiments, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 33-38, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in any of SEQ ID NO: 56-57.
[0051] In any of the above embodiments, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 39-48, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in any of SEQ ID NO: 58-61.
[0052] In any of the above embodiments, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 49-55, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in any of SEQ ID NO: 62-63.
[0053] In any of the above embodiments, the VH has the same sequence HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 33, 34, 35, 36, and the VL has the same sequence LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO: 56.
[0054] In any of the above embodiments, the VH has the same sequence HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 34, 37 and 38, and the VL has the same sequence LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO: 57.
[0055] In any of the above embodiments, the VH has the same sequence HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 39, 40, 41, 42, 43, and the VL has the same sequence LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO: 58.
[0056] In any of the above embodiments, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in SEQ ID NO: 44, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO: 59.
[0057] In any of the above embodiments, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in SEQ ID NO: 45, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO: 60.
[0058] In any of the above embodiments, the VH has the same sequence HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 46, 47 and 48, and the VL has the same sequence LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO: 61.
[0059] In any of the above embodiments, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 49-55, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO: 62.
[0060] In any of the above embodiments, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in SEQ ID NO: 53, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO: 63.
[0061] In any of the above embodiments, the HCDR1, HCDR2 and HCDR3 of the VH, and the LCDR1, LCDR2 and LCDR3 of the VL are defined according to IMGT, Kabat, Chothia, AbM, Contact or any combination thereof.
[0062] In any of the embodiments described above, according to the Kabat definition, HCDR1 comprises the amino acid sequence X1X2TVS (SEQ ID NO: 138), where X1 is selected from S or G, and X2 is selected from H, N, or G; HCDR2 comprises the amino acid sequence RIIPLPX3LX4IX5NYAQKFQD (SEQ ID NO: 139), where X3 is selected from L, G, or T, X4 is selected from T or V, and X5 is selected from P, D, or E; HCDR3 comprises the amino acid sequence DHWX6X7VGNX8X9GMDV (SEQ ID NO: 140), where X6 is selected from D or N, X7 is selected from D, E, Y, or N, X8 is selected from F or M, and X9 is selected from Y, R, L, or Q; and LCDR1 comprises the amino acid sequence RASQGISNX. 10 LA (SEQ ID NO: 141), X 10 Selected from Y or D; the LCDR2 contains the amino acid sequence AX 11 SX 12 LQS (SEQ ID NO: 142), X 11 Selected from A or G, X12 Selected from T or H; the LCDR3 contains the amino acid sequence QKX 13 NSAPLT (SEQ ID NO: 143), X 13 Selected from Y, V, or T;
[0063] Preferably, X1 is G, X2 is selected from N or G, X3 is selected from L, G or T, X4 is selected from T or V, X5 is selected from P, D or E, X6 is selected from D or N, X7 is selected from D, E, Y or N, X8 is selected from F or M, X9 is selected from R, L or Q, X 10 Selected from Y or D, X 11 Selected from A or G, X 12 Selected from T or H, X 13 Selected from V or T;
[0064] Preferably, HCDR1 comprises the amino acid sequences SHTVS (SEQ ID NO: 114), GGTVS (SEQ ID NO: 161), or GNTVS (SEQ ID NO: 162); HCDR2 comprises the amino acid sequences RIIPLPLLTIPNYAQKFQD (SEQ ID NO: 115), RIIPLPGLVIPNYAQKFQD (SEQ ID NO: 144), RIIPLPGLTIDNYAQKFQD (SEQ ID NO: 145), or RIIPLPTLTIENYAQKFQD (SEQ ID NO: 146); and HCDR3 comprises the amino acid sequences DHWDDVGNFYGMDV (SEQ ID NO: 116), DHWDDVGNMRGMDV (SEQ ID NO: 147), DHWDEVGNMLGMDV (SEQ ID NO: 148), DHWDYVGNMLGMDV (SEQ ID NO: 149), or DHWDNVGNMLGMDV (SEQ ID NO: 149). The LCDR1 contains the amino acid sequence RASQGISNYLA (SEQ ID NO: 126) or RASQGISNDLA (SEQ ID NO: 156); the LCDR2 contains the amino acid sequence AASTLQS (SEQ ID NO: 127), AASHLQS (SEQ ID NO: 157) or AGSTLQS (SEQ ID NO: 158); the LCDR3 contains the amino acid sequence QKYNSAPLT (SEQ ID NO: 128), QKVNSAPLT (SEQ ID NO: 159) or QKTNSAPLT (SEQ ID NO: 160).
[0065] More preferably, the HCDR1-3 and LCDR1-3 are selected from the group consisting of:
[0066] (1) HCDR1 contains or is the amino acid sequence SHTVS (SEQ ID NO: 114), HCDR2 contains or is the amino acid sequence RIIPLPLLTIPNYAQKFQD (SEQ ID NO: 115), HCDR3 contains or is the amino acid sequence DHWDDVGNFYGMDV (SEQ ID NO: 116), LCDR1 contains or is the amino acid sequence RASQGISNYLA (SEQ ID NO: 126), LCDR2 contains or is the amino acid sequence AASTLQS (SEQ ID NO: 127), and LCDR3 contains or is the amino acid sequence QKYNSAPLT (SEQ ID NO: 128);
[0067] (2) HCDR1 contains or is the amino acid sequence GGTVS (SEQ ID NO: 161), HCDR2 contains or is the amino acid sequence RIIPLPGLVIPNYAQKFQD (SEQ ID NO: 144), HCDR3 contains or is any of the following amino acid sequences: DHWDDVGNMRGMDV (SEQ ID NO: 147), DHWDEVGNMLGMDV (SEQ ID NO: 148), DHWDYVGNMLGMDV (SEQ ID NO: 149), DHWDNVGNMLGMDV (SEQ ID NO: 150), and DHWNDVGNMLGMDV (SEQ ID NO: 151), LCDR1 contains or is the amino acid sequence RASQGISNDLA (SEQ ID NO: 156), LCDR2 contains or is the amino acid sequence AASTLQS (SEQ ID NO: 127), and LCDR3 contains or is the amino acid sequence QKVNSAPLT (SEQ ID NO: 159);
[0068] (3) HCDR1 contains or is the amino acid sequence GNTVS (SEQ ID NO: 162), HCDR2 contains or is the amino acid sequence RIIPLPGLTIDNYAQKFQD (SEQ ID NO: 145), HCDR3 contains or is the amino acid sequence DHWDDVGNMQGMDV (SEQ ID NO: 152), LCDR1 contains or is the amino acid sequence RASQGISNYLA (SEQ ID NO: 126), LCDR2 contains or is the amino acid sequence AASHLQS (SEQ ID NO: 157), and LCDR3 contains or is the amino acid sequence QKTNSAPLT (SEQ ID NO: 160);
[0069] (4) HCDR1 contains or is the amino acid sequence GGTVS (SEQ ID NO: 161), HCDR2 contains or is the amino acid sequence RIIPLPTLTIENYAQKFQD (SEQ ID NO: 146), HCDR3 contains or is the amino acid sequence DHWDDVGNFQGMDV (SEQ ID NO: 153), LCDR1 contains or is the amino acid sequence RASQGISNDLA (SEQ ID NO: 156), LCDR2 contains or is the amino acid sequence AASTLQS (SEQ ID NO: 127), and LCDR3 contains or is the amino acid sequence QKTNSAPLT (SEQ ID NO: 160);
[0070] (5) HCDR1 contains or is the amino acid sequence GGTVS (SEQ ID NO: 161), HCDR2 contains or is the amino acid sequence RIIPLPLLTIPNYAQKFQD (SEQ ID NO: 115), HCDR3 contains or is the amino acid sequence selected from the group consisting of DHWDDVGNMQGMDV (SEQ ID NO: 152), DHWDYVGNMQGMDV (SEQ ID NO: 154) and DHWDNVGNMQGMDV (SEQ ID NO: 155), LCDR1 contains or is the amino acid sequence RASQGISNDLA (SEQ ID NO: 156), LCDR2 contains or is the amino acid sequence AGSTLQS (SEQ ID NO: 158), and LCDR3 contains or is the amino acid sequence QKVNSAPLT (SEQ ID NO: 159).
[0071] In any of the embodiments described above, according to the Kabat definition, HCDR1 comprises the amino acid sequence X. (1) X (2) X (3) VS (SEQ ID NO: 163), X (1) Selected from S, R, or H, X (2) Selected from H or R, X (3) Selected from T or S; the HCDR2 contains the amino acid sequence RIIPLPX (4) LX (5) IPNYAQKFQD(SEQ ID NO:164),X (4) Selected from L or G, X (5) Selected from T or D; the HCDR3 contains the amino acid sequence DHWDX. (6) VGNFX (7) GX (8) DV (SEQ ID NO: 165), X (6) Selected from D or S, X(7) Selected from Y or R, X (8) Selected from M or S; and, the LCDR1 contains the amino acid sequence KSSQSVLYSX (9) NNKNSLT (SEQ ID NO: 166), X (9) Selected from P or G; the LCDR2 contains the amino acid sequence WASTRX. (10) S(SEQ ID NO: 167), X (10) Selected from E or A; the LCDR3 contains the amino acid sequence QQSYTX (11) PIT (SEQ ID NO: 168), X (11) Selected from F or T;
[0072] Preferably, X (1) Selected from S, R, or H, X (2) Selected from H or R, X (3) Selected from T or S, X (4) Selected from L or G, X (5) Selected from T or D, X (6) Selected from D or S, X (7) Selected from Y or R, X (8) Selected from M or S, X (9) For G, X (10) Selected from E or A, X (11) Let T be the value of T.
[0073] Preferably, HCDR1 comprises the amino acid sequences SHTVS (SEQ ID NO: 114), SHSVS (SEQ ID NO: 169), SRTVS (SEQ ID NO: 170), RHTVS (SEQ ID NO: 171), RHSVS (SEQ ID NO: 172), HHSVS (SEQ ID NO: 173), or HRSVS (SEQ ID NO: 174); HCDR2 comprises the amino acid sequences RIIPLPLLTIPNYAQKFQD (SEQ ID NO: 115), RIIPLPLLDIPNYAQKFQD (SEQ ID NO: 175), RIIPLPGLTIPNYAQKFQD (SEQ ID NO: 176), or RIIPLPGLDIPNYAQKFQD (SEQ ID NO: 177); and HCDR3 comprises the amino acid sequences DHWDDVGNFYGMDV (SEQ ID NO: 116), DHWDDVGNFRGMDV (SEQ ID NO: 117), or RHTVS (SEQ ID NO: 171), RHSVS (SEQ ID NO: 172), HHSVS (SEQ ID NO: 173), or HRSVS (SEQ ID NO: 174); The sequence is SEQ ID NO: 178), DHWDDVGNFYGSDV (SEQ ID NO: 179), or DHWDSVGNFYGMDV (SEQ ID NO: 180); the LCDR1 contains the amino acid sequence KSSQSVLYSPNNKNSLT (SEQ ID NO: 130) or KSSQSVLYSGNNKNSLT (SEQ ID NO: 181); the LCDR2 contains the amino acid sequence WASTRES (SEQ ID NO: 131) or WASTRAS (SEQ ID NO: 182); the LCDR3 contains the amino acid sequence QQSYTFPIT (SEQ ID NO: 132) or QQSYTTPIT (SEQ ID NO: 183);
[0074] More preferably, the HCDR1-3 and LCDR1-3 are selected from the group consisting of:
[0075] (1) HCDR1 contains or is the amino acid sequence SHTVS (SEQ ID NO: 114), HCDR2 contains or is the amino acid sequence RIIPLPLLTIPNYAQKFQD (SEQ ID NO: 115), HCDR3 contains or is the amino acid sequence DHWDDVGNFYGMDV (SEQ ID NO: 116), LCDR1 contains or is the amino acid sequence KSSQSVLYSPNNKNSLT (SEQ ID NO: 130), LCDR2 contains or is the amino acid sequence WASTRES (SEQ ID NO: 131), and LCDR3 contains or is the amino acid sequence QQSYTFPIT (SEQ ID NO: 132);
[0076] (2) HCDR1 contains or is the amino acid sequence SHSVS (SEQ ID NO: 169), HCDR2 contains or is the amino acid sequence RIIPLPLLDIPNYAQKFQD (SEQ ID NO: 175), HCDR3 contains or is the amino acid sequence DHWDDVGNFRGMDV (SEQ ID NO: 178); LCDR1 contains or is the amino acid sequence KSSQSVLYSGNNKNSLT (SEQ ID NO: 181), LCDR2 contains or is the amino acid sequence WASTRAS (SEQ ID NO: 182), and LCDR3 contains or is the amino acid sequence QQSYTTPIT (SEQ ID NO: 183);
[0077] (3) HCDR1 contains or is the amino acid sequence SRTVS (SEQ ID NO: 170), HCDR2 contains or is the amino acid sequence RIIPLPGLTIPNYAQKFQD (SEQ ID NO: 176), HCDR3 contains or is the amino acid sequence DHWDDVGNFYGSDV (SEQ ID NO: 179), LCDR1 contains or is the amino acid sequence KSSQSVLYSGNNKNSLT (SEQ ID NO: 181), LCDR2 contains or is the amino acid sequence WASTRAS (SEQ ID NO: 182), and LCDR3 contains or is the amino acid sequence QQSYTTPIT (SEQ ID NO: 183);
[0078] (4) HCDR1 contains or is the amino acid sequence RHTVS (SEQ ID NO: 171), HCDR2 contains or is the amino acid sequence RIIPLPGLTIPNYAQKFQD (SEQ ID NO: 176), HCDR3 contains or is the amino acid sequence DHWDDVGNFRGMDV (SEQ ID NO: 178), LCDR1 contains or is the amino acid sequence KSSQSVLYSGNNKNSLT (SEQ ID NO: 181), LCDR2 contains or is the amino acid sequence WASTRAS (SEQ ID NO: 182), and LCDR3 contains or is the amino acid sequence QQSYTTPIT (SEQ ID NO: 183).
[0079] (5) HCDR1 contains or is the amino acid sequence RHSVS (SEQ ID NO: 172) or HHSVS (SEQ ID NO: 173), HCDR2 contains or is the amino acid sequence RIIPLPGLTIPNYAQKFQD (SEQ ID NO: 176), HCDR3 contains or is the amino acid sequence DHWDDVGNFYGMDV (SEQ ID NO: 116), LCDR1 contains or is the amino acid sequence KSSQSVLYSGNNKNSLT (SEQ ID NO: 181), LCDR2 contains or is the amino acid sequence WASTRAS (SEQ ID NO: 182), and LCDR3 contains or is the amino acid sequence QQSYTTPIT (SEQ ID NO: 183);
[0080] (6) HCDR1 contains or is the amino acid sequence HRSVS (SEQ ID NO: 174), HCDR2 contains or is the amino acid sequence RIIPLPGLDIPNYAQKFQD (SEQ ID NO: 177), HCDR3 contains or is the amino acid sequence DHWDDVGNFYGMDV (SEQ ID NO: 116), LCDR1 contains or is the amino acid sequence KSSQSVLYSGNNKNSLT (SEQ ID NO: 181), LCDR2 contains or is the amino acid sequence WASTRAS (SEQ ID NO: 182), and LCDR3 contains or is the amino acid sequence QQSYTTPIT (SEQ ID NO: 183).
[0081] (7) HCDR1 contains or is the amino acid sequence SHTVS (SEQ ID NO: 114), HCDR2 contains or is the amino acid sequence RIIPLPGLTIPNYAQKFQD (SEQ ID NO: 176), HCDR3 contains or is the amino acid sequence DHWDSVGNFYGMDV (SEQ ID NO: 180), LCDR1 contains or is the amino acid sequence KSSQSVLYSGNNKNSLT (SEQ ID NO: 181), LCDR2 contains or is the amino acid sequence WASTRAS (SEQ ID NO: 182), and LCDR3 contains or is the amino acid sequence QQSYTTPIT (SEQ ID NO: 183);
[0082] (8) HCDR1 contains or is the amino acid sequence HHSVS (SEQ ID NO: 173), HCDR2 contains or is the amino acid sequence RIIPLPGLTIPNYAQKFQD (SEQ ID NO: 176), HCDR3 contains or is the amino acid sequence DHWDDVGNFYGMDV (SEQ ID NO: 116), LCDR1 contains or is the amino acid sequence KSSQSVLYSGNNKNSLT (SEQ ID NO: 181), LCDR2 contains or is the amino acid sequence WASTRES (SEQ ID NO: 131), and LCDR3 contains or is the amino acid sequence QQSYTTPIT (SEQ ID NO: 183).
[0083] In any of the embodiments described above, according to the Kabat definition, HCDR1 comprises the amino acid sequence DTYIH (SEQ ID NO: 120), and HCDR2 comprises the amino acid sequence RIDREX. [1] GDIX [2] YAX [3] X [4] FQG (SEQ ID NO: 184), X [1] Selected from N or Q, X [2] Selected from E or N, X [3] Selected from P, Q, or E, X [4] Selected from N or K; HCDR3 contains the amino acid sequence PGYYDWGGFAY (SEQ ID NO: 122); LCDR1 contains the amino acid sequence KASQNVDX [5] NVA (SEQ ID NO: 185), X [5] Selected from T or Y; LCDR2 contains the amino acid sequence SASYRYS (SEQ ID NO: 135); LCDR3 contains the amino acid sequence QQYHSFPRT (SEQ ID NO: 136);
[0084] Preferably, HCDR1 contains the amino acid sequence DTYIH (SEQ ID NO: 120); HCDR2 contains the amino acid sequences RIDRENGDIEYAPNFQG (SEQ ID NO: 121), RIDRENGDIEYAQKFQG (SEQ ID NO: 186), RIDRENGDIEYAEKFQG (SEQ ID NO: 187), RIDREQGDIEYAPNFQG (SEQ ID NO: 188), or RIDREQGDINYAQKFQG (SEQ ID NO: 189); HCDR3 contains the amino acid sequence PGYYDWGGFAY (SEQ ID NO: 122); LCDR1 contains the amino acid sequence KASQNVDTNVA (SEQ ID NO: 134) or KASQNVDYNVA (SEQ ID NO: 190); LCDR2 contains the amino acid sequence SASYRYS (SEQ ID NO: 135); and LCDR3 contains the amino acid sequence QQYHSFPRT (SEQ ID NO: 136).
[0085] More preferably, the HCDR1-3 and LCDR1-3 are selected from the group consisting of:
[0086] (1) HCDR1 contains or is the amino acid sequence DTYIH (SEQ ID NO: 120), HCDR2 contains or is the amino acid sequence RIDRENGDIEYAPNFQG (SEQ ID NO: 121), HCDR3 contains or is the amino acid sequence PGYYDWGGFAY (SEQ ID NO: 122), LCDR1 contains or is the amino acid sequence KASQNVDTNVA (SEQ ID NO: 134) or KASQNVDYNVA (SEQ ID NO: 190), LCDR2 contains or is the amino acid sequence SASYRYS (SEQ ID NO: 135), and LCDR3 contains or is the amino acid sequence QQYHSFPRT (SEQ ID NO: 136);
[0087] (2) HCDR1 contains or is the amino acid sequence DTYIH (SEQ ID NO: 120), HCDR2 contains or is the amino acid sequence RIDRENGDIEYAQKFQG (SEQ ID NO: 186), HCDR3 contains or is the amino acid sequence PGYYDWGGFAY (SEQ ID NO: 122), LCDR1 contains or is the amino acid sequence KASQNVDTNVA (SEQ ID NO: 134), LCDR2 contains or is the amino acid sequence SASYRYS (SEQ ID NO: 135), and LCDR3 contains or is the amino acid sequence QQYHSFPRT (SEQ ID NO: 136);
[0088] (3) HCDR1 contains or is the amino acid sequence DTYIH (SEQ ID NO: 120), HCDR2 contains or is the amino acid sequence RIDRENGDIEYAEKFQG (SEQ ID NO: 187), HCDR3 contains or is the amino acid sequence PGYYDWGGFAY (SEQ ID NO: 122), LCDR1 contains or is the amino acid sequence KASQNVDTNVA (SEQ ID NO: 134), LCDR2 contains or is the amino acid sequence SASYRYS (SEQ ID NO: 135), and LCDR3 contains or is the amino acid sequence QQYHSFPRT (SEQ ID NO: 136);
[0089] (4) HCDR1 contains or is the amino acid sequence DTYIH (SEQ ID NO: 120), HCDR2 contains or is the amino acid sequence RIDREQGDIEYAPNFQG (SEQ ID NO: 188), HCDR3 contains or is the amino acid sequence PGYYDWGGFAY (SEQ ID NO: 122), LCDR1 contains or is the amino acid sequence KASQNVDYNVA (SEQ ID NO: 190), LCDR2 contains or is the amino acid sequence SASYRYS (SEQ ID NO: 135), and LCDR3 contains or is the amino acid sequence QQYHSFPRT (SEQ ID NO: 136);
[0090] (5) HCDR1 contains or is the amino acid sequence DTYIH (SEQ ID NO: 120), HCDR2 contains or is the amino acid sequence RIDREQGDINYAQKFQG (SEQ ID NO: 189), HCDR3 contains or is the amino acid sequence PGYYDWGGFAY (SEQ ID NO: 122), LCDR1 contains or is the amino acid sequence KASQNVDYNVA (SEQ ID NO: 190), LCDR2 contains or is the amino acid sequence SASYRYS (SEQ ID NO: 135), and LCDR3 contains or is the amino acid sequence QQYHSFPRT (SEQ ID NO: 136).
[0091] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 1, 3, 5, 7, 39-55, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 2, 4, 6, 8, 58-63.
[0092] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33-38, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 56-57.
[0093] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 1, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 2.
[0094] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 3, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 4.
[0095] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 31, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 32.
[0096] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 33, 34, 35, or 36, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 56.
[0097] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 34, 37, or 38, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 57.
[0098] In any of the embodiments of the foregoing aspects, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 39, 40, 41, 42, 43, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 58.
[0099] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 44, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 59.
[0100] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 45, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 60.
[0101] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 46, 47, or 48, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 61.
[0102] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 49-55, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 62.
[0103] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 53, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 63.
[0104] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 38, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 57.
[0105] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 42, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 58.
[0106] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 48, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 61.
[0107] In any of the embodiments of the foregoing aspects, the VH and VL are selected from the group consisting of: the VH and VL respectively comprising, or consisting of, the sequences shown in SEQ ID NO: 1 and 2; the VH and VL respectively comprising, or consisting of, the sequences shown in SEQ ID NO: 3 and 4; the VH and VL respectively comprising, or consisting of, the sequences shown in SEQ ID NO: 5 and 6; the VH and VL respectively comprising, or consisting of, the sequences shown in SEQ ID NO: 7 and 8; the VH and VL respectively comprising, or consisting of, the sequences shown in SEQ ID NO: 9 and 10; the VH and VL respectively comprising, or consisting of, the sequences shown in SEQ ID NO: 11 and 12; the VH and VL respectively comprising, or consisting of, the sequences shown in SEQ ID NO: 13 and 14; the VH and VL respectively comprising, or consisting of, the sequences shown in SEQ ID NO: 15 and 16; the VH and VL respectively comprising, or consisting of, the sequences shown in SEQ ID NO: 1 ... The sequences shown in SEQ ID NO: 17 and 18, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 19 and 20, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 21 and 22, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 23 and 24, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 25 and 26, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 27 and 28, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 29 and 30, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 31 and 32, or composed thereof; the VH contains the sequences shown in SEQ ID NO: 33, 34, 35, and 36, and the VL contains the sequence shown in SEQ ID NO: 56, or composed thereof; the VH contains the sequences shown in SEQ ID NO: 19 and 20, or composed thereof; the VH contains the sequences shown in SEQ ID NO: 21 and 22, or composed thereof; the VH contains the sequences shown in SEQ ID NO: 23 and 24, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 25 and 26, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 27 and 28, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 29 and 30, or composed thereof; the VH and VL respectively contain the sequences shown in SEQ ID NO: 31 and 32, or composed thereof; the VH contains the sequences shown in SEQ ID NO: 33, 34, 35, and 36, and the VL contains the sequences shown in SEQ ID NO: The sequence shown in SEQ ID NO: 34, 37, 38 and the VL contain or consist of the sequence shown in SEQ ID NO: 57; the VH contains or consists of the sequence shown in SEQ ID NO: 39, 40, 41, 42, 43 and the VL contains or consists of the sequence shown in SEQ ID NO: 58; the VH and VL each contain or consist of the sequences shown in SEQ ID NO: 44, 59; the VH and VL each contain or consist of the sequences shown in SEQ ID NO: 45, 60; the VH contains or consists of the sequence shown in SEQ ID NO: 46, 47, 48 and the VL contains or consists of the sequence shown in SEQ ID NO: 61.The VH comprises, or consists of, any of the sequences shown in SEQ ID NO: 49-55, and the VL comprises, or consists of, the sequence shown in SEQ ID NO: 62; or, the VH and VL respectively comprise, or consist of, the sequences shown in SEQ ID NO: 53 and 63.
[0108] In any of the above embodiments, the VH and VL are selected from the group consisting of:
[0109] (1) VH contains or consists of the following amino acid sequence:
[0110] QVQLMQSGAEVKKPGSSVKISCKASGGTFTSHTVSWVRQAPGQGLEWMGRIIPLPLLTIPNYAQKFQDRLTITADKSTTTSYMELSSLRSDDTAVYFCARDHWDDVGNFYGMDVWGQGTTVTVSS (SEQ ID NO: 69); and VL contains or is the following amino acid sequence:
[0111] (2) VH contains or is the following amino acid sequence:
[0112] QMQLVQSGAEVKKPGSSVKISCKASGGTFTSHTVSWVRQAPGQGLEWMGRIIPLPLLTIPNYAQKFQDRLTITADKSTTTSYMELSSLRSDDTAVYFCARDHWDDVGNFYGMDVWGQGTTVTVSS (SEQ ID NO: 71); and VL contains or is the following amino acid sequence:
[0113] (3) VH contains or consists of the following amino acid sequence:
[0114] EIQLQQSGAEFVKPGASVKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIDRENGDIEYAPNFQGKATITADISSNTAYLQLSSLTSEDTAVYYCAAPGYYDWGGFAYWGQGTLVTVSA (SEQ ID NO: 73); and, VL contains or is the following amino acid sequence:
[0115] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 69, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 70.
[0116] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 71, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 72.
[0117] In any of the embodiments described above, the VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 73, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 74.
[0118] In any of the above embodiments, VH and VL respectively comprise SEQ ID NO: 53, 63, or are composed of therewith; VH and VL respectively comprise SEQ ID NO: 38, 57, or are composed of therewith; VH and VL respectively comprise SEQ ID NO: 42, 58, or are composed of therewith; or VH and VL respectively comprise SEQ ID NO: 48, 61, or are composed of therewith.
[0119] In any of the embodiments described above, the anti-GIPR antibody provided herein further comprises a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region is selected from the constant regions of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE or variants thereof, preferably from, for example, the constant regions of human IgG1, IgG2, IgG3, and IgG4 or variants thereof; and the light chain constant region is selected from the κ and λ chain constant regions or variants thereof, preferably from the human κ and λ chain constant regions or variants thereof. The variant has altered effector functions mediated by the Fc region (e.g., ADCC and / or CDC activity, affinity for FcγRIIIa and / or C1q), but does not alter the function of the antibody variable region. In some embodiments, the variant Fc region has at least one amino acid substitution compared to the wild-type Fc region, for example, about 1-10 amino acid substitutions, or about 1-5 amino acid substitutions, or about 1-3 amino acid substitutions in the wild-type Fc region. The variant Fc region may have at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homology with the wild-type Fc region. In some embodiments, the antibody or its antigen-binding fragment comprises a constant region variant of human IgG1, which has one or more of the following substitutions compared to its derived wild-type sequence: N297A, N297G, E272C, R292C, V302C, L234A, L235A, P329G, M428L, N434S (according to the EU numbering system). In some embodiments, the variant has one or more substitutions selected from the following compared to its derived wild-type sequence: M428L / N434S (LS mutation), L234A / L235A / P329G (LALA-PG mutation), and L234A / L235A (LALA mutation). In some preferred embodiments, the heavy chain constant region comprises a sequence as shown in any of SEQ ID NO: 64, 66, 68, or 113, and the light chain constant region comprises a sequence as shown in SEQ ID NO: 65. In some preferred embodiments, the heavy chain constant region comprises a sequence as shown in any of SEQ ID NO: 64, 66, 68, or 113, and the light chain constant region comprises a sequence as shown in SEQ ID NO: 67.
[0120] In any of the embodiments described above, the VL is selected from any of the sequences shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and the light chain constant region comprises the sequence shown in SEQ ID NO: 65. In some embodiments, the VL is selected from any of the sequences shown in SEQ ID NO: 56-63, and the light chain constant region comprises the sequence shown in SEQ ID NO: 67.
[0121] In any of the embodiments described above, the anti-GIPR antibody provided herein is selected from SGIP-P35, SGIP-P37, SGIP-P69, SGIP-P11, SGIP-B175, SGIP-B190, SGIP-B194, SGIP-B054, SGIP-B117, SGIP-B225, SGIP-B249, SGIP-B252, SGIP-B253, SGIP-B254, and SGIP-B255. In some preferred embodiments, the anti-GIPR antibody is selected from SGIP-P35, SGIP-P37, SGIP-P69, SGIP-B175, SGIP-B190, SGIP-B194, and SGIP-H183. In some preferred embodiments, the anti-GIPR antibody is selected from SGIP-H183.A, SGIP-H183.B, SGIP-H183.C, SGIP-H183.D, SGIP-H183.E, SGIP-H183.F, and SGIP-H183.G. In some preferred embodiments, the anti-GIPR antibody is selected from SGIP-P35.A, SGIP-P35.B, SGIP-P35.C, SGIP-P35.D, SGIP-P35.E, SGIP-P35.F, SGIP-P35.G, SGIP-P35.H, SGIP-P35.I, SGIP-P35.J, and SGIP-P35.JS. In some preferred embodiments, the anti-GIPR antibody is selected from SGIP-P37.A, SGIP-P37.B, SGIP-P37.C, SGIP-P37.D, SGIP-P37.E, SGIP-P37.F, SGIP-P37.G, and SGIP-P37.H. In some preferred embodiments, the anti-GIPR antibody is selected from SGIP-H183.G, SGIP-P35.G, SGIP-P35.J, SGIP-P37.H, and SGIP-P35.JS.
[0122] In any of the embodiments described above, the anti-GIPR antibody or its antigen-binding fragment comprises a heavy chain and a light chain, the heavy chain having an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 98%, 99%, or 100% identical to the sequence shown in any one of SEQ ID NO: 75, 77, 79, 81, 83, 85, 87, 89, 90, 91, 92, 93, 94, 95, 96, 98, 99, 100, 101, 102, 103, 105, 107, 109, 110, 111, or 112, and / or the light chain having an amino acid sequence that is identical to the sequence shown in SEQ ID NO: 75, 77, 79, 81, 83, 85, 87, 109, 110, 111, or 112, and / or the light chain having an amino acid sequence that is identical to the sequence shown in SEQ ID NO: 75, 77, 79, 81, 83, 85, 87, 109, 110, 111, or 112, and / or the light chain having an amino acid sequence that is identical to the sequence shown in SEQ ID NO: 75, 77, 79, 81, 83, 85, 10 ... NO: 76, 78, 80, 82, 84, 86, 88, 97, 104, 106, 108. The amino acid sequence is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of these sequences. In some embodiments, the heavy and light chains have at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a combination of heavy and light chains selected from the group consisting of:
[0123] (1) The heavy chain shown in SEQ ID NO: 75 and / or the light chain shown in SEQ ID NO: 76;
[0124] (2) The heavy chain shown in SEQ ID NO: 77 and / or the light chain shown in SEQ ID NO: 78;
[0125] (3) The heavy chain shown in SEQ ID NO: 79 and / or the light chain shown in SEQ ID NO: 80;
[0126] (4) The heavy chain shown in any of SEQ ID NO: 81, 89, 90, 91, 92 and / or the light chain shown in SEQ ID NO: 82;
[0127] (5) The heavy chain shown in SEQ ID NO: 83 and / or the light chain shown in SEQ ID NO: 84;
[0128] (6) The heavy chain shown in SEQ ID NO: 85 and / or the light chain shown in SEQ ID NO: 86;
[0129] (7) The heavy chain shown in any of SEQ ID NO: 87, 93, 94, 95 and / or the light chain shown in SEQ ID NO: 88;
[0130] (8) The heavy chain shown in any of SEQ ID NO: 96, 98, 99, 100, 101, 102, 103 and / or the light chain shown in SEQ ID NO: 97;
[0131] (9) The heavy chain shown in SEQ ID NO: 101 and / or the light chain shown in SEQ ID NO: 104;
[0132] (10) The heavy chain shown in any of SEQ ID NO: 105, 107, 109, 110 and / or the light chain shown in SEQ ID NO: 106; or
[0133] (11) The heavy chain shown in any of SEQ ID NO: 107, 111, 112 and / or the light chain shown in SEQ ID NO: 108.
[0134] In any of the embodiments described above, the anti-GIPR antibody or its antigen-binding fragment has at least one of the following functions:
[0135] (1) When binding to human GIPR, the antibody or its antigen-binding fragment has a KD of less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 1 nM or lower;
[0136] (2) When bound to human GIPR, the KD of the antibody or its antigen-binding fragment is substantially the same as or better than that of the reference GIPR antibody;
[0137] (3) When bound to human GIPR, the antibody or its antigen-binding fragment inhibits or blocks GIP signal transduction;
[0138] (4) When inhibiting or blocking the GIP activation of human GIPR, the inhibitory or blocking effect of the antibody or its antigen-binding fragment is basically the same as or better than that of the reference GIPR antibody.
[0139] (5) It can lower blood sugar;
[0140] (6) It can increase glucose tolerance;
[0141] (7) It can increase insulin sensitivity;
[0142] (8) It can reduce weight or decrease weight gain;
[0143] (9) It can reduce fat mass or reduce inflammation of adipose tissue;
[0144] (10) It can lower fasting insulin levels;
[0145] (11) It can lower circulating cholesterol levels;
[0146] (12) It can reduce circulating triglyceride levels;
[0147] (13) It can reduce hepatic steatosis or lower triglyceride levels in the liver;
[0148] (14) Reduce AST, ALT and / or ALP levels;
[0149] (15) Inhibit or block the binding of GIP to the extracellular portion of human GIPR;
[0150] (16) It can reduce liver weight or reduce the increase in liver weight;
[0151] KD can be determined using methods known to those skilled in the art, such as using a Fortebio molecular interaction analyzer, or using the method provided in Example 2 of this invention.
[0152] In any of the embodiments described above, the reference GIPR antibody may be prepared in accordance with patents CN110662558, CN109715662, CN114641495, and CN117480186, which are incorporated herein by reference in their entirety. In some specific embodiments, the reference GIPR antibody may be prepared in accordance with antibody 2G10_LC1.006 of patent CN110662558. In some specific embodiments, the reference GIPR antibody is Maridebart.
[0153] In any of the embodiments described above, the anti-GIPR antibody or its antigen-binding fragment is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody. In some embodiments, the anti-GIPR antibody is a monoclonal antibody.
[0154] In any of the above embodiments, the antigen-binding fragment is selected from: Fab, F(ab')2, Fab', Fd, Fv, dsFv, scFv and biantibodies.
[0155] In embodiments of any of the foregoing aspects, the GLP-1 / GCG dual receptor agonist is selected from gastrin (OXM) or its analogues, glucagon or its analogues. In some embodiments, the OXM analogue has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations (amino acid mutations include substitutions, insertions, and / or deletions) compared to its derived natural OXM. In some embodiments, the OXM analogue has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity compared to its derived natural OXM. In some embodiments, the OXM analogue has side-chain modifications of amino acid residues compared to its derived natural OXM, including but not limited to fatty acid chain modifications, PEG chain modifications, etc. In some embodiments, the glucagon analog has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations (amino acid mutations include substitutions, insertions, and / or deletions) compared to its derived natural glucagon. In some embodiments, the glucagon analog has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity compared to its derived natural glucagon. In some embodiments, the glucagon analog has side-chain modifications of amino acid residues compared to its derived natural glucagon, including but not limited to fatty acid chain modifications, PEG chain modifications, etc.
[0156] In embodiments of any of the foregoing aspects, specific examples of GLP-1 / GCG dual receptor agonists are disclosed in WO 2006 / 134340, WO 2007 / 100535, WO 2008 / 10101, WO 2008 / 152403, WO 2009 / 155257, WO Patent documents 2009 / 155258, WO2010 / 070252, WO2010 / 070253, WO2010 / 070255, WO2010 / 070251, WO2011 / 006497, WO2011 / 160630, WO2011 / 160633, WO2013 / 092703, WO2014 / 041195, WO2015 / 055801, and WO2016 / 209707 are included in this paper by full citation.
[0157] In any of the embodiments described above, the GLP-1 / GCG dual receptor agonist is selected from Survodutide, whose polypeptide sequence is: HH-Ac4c-QGTFTSDYSKYLDERAAKDFI-K([17-carboxy-heptadecanoyl]-isoGlu-GSGSGG)-WLESA-NH2 (SEQ ID NO: 191), and its structural formula is as follows:
[0158] In any of the embodiments described above, the GLP-receptor agonist is selected from GLP-1 (7-37) or its analogues. In some embodiments, the GLP-1 (7-37) analogue has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations (amino acid mutations include substitutions, insertions, and / or deletions) compared to its derived natural GLP-1 (7-37). In some embodiments, the GLP-1 (7-37) analogue has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity compared to its derived natural GLP-1 (7-37). In some embodiments, the GLP-1 (7-37) analogue has side-chain modifications of amino acid residues compared to its derived natural GLP-1 (7-37), including but not limited to fatty acid chain modifications, PEG chain modifications, etc. GLP-1(7-37) or its analogues may optionally be amidated.
[0159] In any of the embodiments described above, specific examples of GLP-1 receptor agonists are disclosed in patent documents such as WO2006097537, WO2005000892, WO1998008871, WO2005077042, CN1381272A, CN101273134B, and CN110386975B, which are incorporated herein by reference in their entirety.
[0160] In any of the embodiments described above, the GLP-1 receptor agonist is selected from exenatide, liraglutide, lixilatide, abiglutide, dulaglutide, semaglutide, benaglutide, supaglutide, and tasglutide. The structural formula of semaglutide is as follows (SEQ ID NO: 192):
[0161] In any of the embodiments described above, the salt of the GLP-1 / GCG dual receptor agonist or the salt of the GLP-1 receptor agonist is selected from at least one of lithium, sodium, potassium, calcium, magnesium, aluminum, iron, zinc, or ammonium salts; or the salt is selected from hydrochloride, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, 2-ethylaminoethanol, pyridine, methylpyridine, ethanolamine, diethanolamine, or diethanolamine. At least one of the following: amine salt, ammonium salt, tetramethylammonium salt, tetraethylammonium salt, triethanolamine salt, piperidine salt, piperazine salt, morpholine salt, lysine salt, L-lysine salt, arginine salt, L-arginine salt, histidine salt, L-histidine salt, meglumine salt, dimethylglucosamine salt, ethylglucosamine salt, dicyclohexylamine salt, 1,6-hexanediamine salt, glucosamine salt, sarcosine salt, serine salt, trihydroxymethylaminomethane salt, aminopropylene glycol salt, ornithine salt, or choline salt.
[0162] The anti-GIPR antibodies or their antigen-binding fragments described herein can be obtained using conventional techniques, such as the Cold Spring Harbor Laboratory Antibody Techniques Guide, Chapters 5-8 and 15. For example, mice can be immunized with human GIPR or fragments thereof, and the resulting antibodies can be refolded, purified, and sequenced using conventional methods. The antigen-binding fragments can also be prepared using conventional methods. The antibodies or antigen-binding fragments described in this invention are prepared by adding one or more human FR regions to a non-human CDR region using genetic engineering methods. Human FR germline sequences can be obtained from the ImMunoGeneTics (IMGT) website by comparing with the IMGT Human Antibody Variable Region Germplasm Database and MOE software, or from the Journal of Immunoglobulins, 2001 ISBN012441351. Alternatively, cDNA sequences encoding the heavy and light chains can be cloned into expression vectors, for example. The recombinant immunoglobulin expression vectors can be stably transfected into CHO cells. Stable clones are obtained by expressing antibodies that specifically bind to human GIPR. Positive clones are scaled up in serum-free medium in a bioreactor to produce antibodies.
[0163] The anti-GIPR antibody or its antigen-binding fragment described herein can be expressed intracellularly, on the cell membrane, or secreted extracellularly. If desired, the recombinant protein can be isolated and purified using various separation methods based on its physical, chemical, and other properties. These methods are well known to those skilled in the art. Typically, host cells transformed with the antibody are cultured under conditions suitable for antibody expression, and then purified using conventional immunoglobulin purification steps, such as protein A-Sepharose affinity chromatography, ion exchange chromatography, hydrophobic chromatography, molecular sieve chromatography, hydroxyapatite chromatography, gel electrophoresis, dialysis, and other conventional separation and purification techniques, or combinations thereof, to obtain the anti-GIPR antibody or its antigen-binding fragment described herein. The antibody can be filtered and concentrated using conventional methods.
[0164] As a preferred embodiment of the preparation method of the anti-GIPR antibody or its antigen-binding fragment described herein, the method for separating and purifying the anti-GIPR antibody or its antigen-binding fragment is protein A affinity chromatography, cation exchange, or anion exchange.
[0165] The resulting monoclonal or bispecific antibodies can be identified using conventional methods. For example, the binding specificity of an antibody can be determined by immunoprecipitation or in vitro binding assays, such as enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay (RIA). The binding affinity of an antibody can be determined, for example, by Scatchard analysis (Munson et al., Anal. Biochem., 107:220 (1980)) or by surface plasmon resonance (Biacore).
[0166] For clarity, this article defines the general terminology used in the description of compounds.
[0167] Unless otherwise stated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered uncertain or unclear unless specifically defined, but should be understood in its ordinary sense. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredient. The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without undue toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0168] The terms “GIPR (gastric inhibitory polypeptide receptor),” “GIP receptor,” and “gastric inhibitory peptide receptor” are used interchangeably to refer to any GIPR molecule and its functional homologs known to those skilled in the art. Unless otherwise stated, GIPR includes, but is not limited to, those derived from humans, rodents, mice, rats, primates, monkeys, and guinea pigs. The term also refers to fragments or variants of natural GIPRs that retain at least one in vivo or in vitro activity of the natural GIPR, such as GIP-binding activity. The term includes both the full-length, unprocessed precursor form of GIPR and the mature form resulting from post-translational cleavage of the signal peptide. As used herein, GIPR also refers to a specific polypeptide expressed in cells via naturally occurring DNA sequence variations in the GIPR gene, such as single nucleotide polymorphisms of the GIPR gene. Examples of amino acid sequences corresponding to human GIPRs registered with GenBank accessions NP_000155.1 or NP_001295347.1 may be cited. Other examples of GIPR amino acid sequences are available from, for example, GenBank, UniProt, and OMIM.
[0169] The term "GLP-1 / GCG dual receptor agonist" refers to a substance (e.g., peptides, small molecule compounds) that can simultaneously activate both GLP-1 and GCG receptors.
[0170] The term "GLP-1 receptor agonist" refers to a compound having GLP-1 receptor activity. Exemplary GLP-1 receptor agonists include exenatide, exenatide analogs, exenatide agonists, GLP-1(7-37), GLP-1(7-37) analogs, GLP-1(7-37) agonists, etc. GLP-1 receptor agonist compounds may optionally be amidated. Various GLP-1 receptor agonists are known in the art and described, for example, in WO2018136440, WO2006097537, WO2005000892, and WO1998008871, which are incorporated herein by reference in their entirety. GLP-1(7-37) refers to the natural GLP-1(7-37) sequence with the amino acid sequence: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (SEQ ID NO: 193). GLP-1(7-37) analogues are polypeptides obtained by modifying natural GLP-1(7-37) amino acids. The modifications include deletion (removal) and / or substitution (replacement) and / or addition (extension) of one or more amino acid residues. The amino acids can be naturally occurring amino acids or artificially synthesized amino acids.
[0171] The term "pharmaceutically acceptable salt" refers to a salt of a GLP-1 / GCG dual receptor agonist or a GLP-1 receptor agonist, prepared by reacting the GLP-1 / GCG dual receptor agonist or a GLP-1 receptor agonist with a relatively non-toxic acid or base. When the GLP-1 / GCG dual receptor agonist or GLP-1 receptor agonist contains a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of such GLP-1 / GCG dual receptor agonist or GLP-1 receptor agonist with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine, or magnesium salts or similar salts. When a GLP-1 / GCG dual receptor agonist or a GLP-1 receptor agonist contains a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of such a GLP-1 / GCG dual receptor agonist or GLP-1 receptor agonist with a sufficient amount of acid in a pure solution or a suitable inert solvent.
[0172] The term "antibody" as used herein includes complete antibodies and any antigen-binding fragment (i.e., "antigen-binding moiety") or its single chain. A complete antibody is a glycoprotein consisting of two heavy (H) chains and two light (L) chains linked together by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated VH herein) and a heavy chain constant region (abbreviated CH herein). The heavy chain constant region consists of three domains: CH1, CH2, and CH3. Each light chain consists of a light chain variable region (abbreviated VL herein) and a light chain constant region (abbreviated CL herein). The light chain constant region consists of one domain: CL. The VH and VL regions can be further subdivided into hypervariable regions (called complementarity-determining regions (CDRs)) separated by more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3. The variable regions of both the heavy and light chains contain binding domains that interact with antigens. The constant regions of antibodies can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0173] The determination or definition of a CDR can be accomplished by resolving the structure of the antibody and / or the structure of the antibody-ligand complex, thereby enabling the definitive depiction of the CDR and the identification of residues containing the antibody binding site. This can be achieved using any of a variety of techniques known to those skilled in the art, such as X-ray crystallography. Various analytical methods (including combinations of methods) can be used to identify CDRs, including but not limited to Kabat definition, Chothia definition, AbM definition, IMGT definition, Contact definition, and conformational definition. All of these techniques are well-known in the art; see, for example, Kabat, E.A. et al. (1991), Sequences of Proteins of Immunological Interest, 5th Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia, et al. (1989), Nature 342:877; Chothia, C. et al. (1987), J. Mol. Biol. 196:901-917; Allazikani, et al. (1997), J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit. 17:132-143 (2004). The boundaries of a given CDR can vary depending on the method used for identification. Therefore, unless otherwise stated, the term "CDR" for a given antibody or its region (such as a variable region), and individual CDRs (e.g., HCDR1, HCDR2) of an antibody or its region, should be understood to encompass complementarity-determining regions as defined above by any known method described herein. In some cases, schemes for identifying a particular CDR or multiple CDRs (such as CDRs defined by the IMGT, Kabat, Chothia, or Contact methods) are described. In other cases, a specific amino acid sequence of the CDR is given. It should be noted that CDR regions can also be defined by combinations of various numbering systems (e.g., a combination of Kabat and Chothia or a combination of Kabat and IMGT). Therefore, once a variable region (e.g., VH or VL) is given, those skilled in the art will understand that CDRs within that region can be defined by different numbering systems or combinations thereof.
[0174] CDRs can also be identified using software programs, including but not limited to AbRSA (http: / / cao.labshare.cn / AbRSA / cdrs.php), abYsis (www.abysis.org / abysis / sequence_input / key_annotation / key_annotation.cgi), and IMGT (http: / / www.imgt.org / 3Dstructure-DB / cgi / DomainGapAlign.cgi#results). The positions of amino acid residues included in an exemplary defined CDR are listed in the table below:
[0175] Note 1: The definitions in different documents vary slightly, especially the definition scheme of Chothia;
[0176] Note 2: Except for the Contact definition which uses the Chothia or Martin numbering scheme, other definition schemes are compatible with various numbering schemes;
[0177] Note 3: When using Kabat numbering, the end of Chothia HCDR1 varies between H32 and H34 depending on the length of the ring (this is because the Kabat numbering scheme places the insertion at H35A and H35B).
[0178] The term “antigen-binding fragment” (or simply “antibody fraction”) refers to one or more fragments of an antibody that specifically bind to an antigen (e.g., GIPR). Antigen-binding functionality of antibodies has been demonstrated to be achieved through fragments of full-length antibodies. Examples of binding fragments covered by the term “antigen-binding fragment” of an antibody include: (i) Fab fragments, monovalent fragments consisting of VL, VH, CL, and CH1 domains; (ii) F(ab')2 fragments, bivalent fragments containing two Fab fragments linked by disulfide bonds in a hinge region; (iii) Fd fragments consisting of VH and CH1 domains; (iv) Fv fragments consisting of VL and VH domains in a single arm of an antibody; (v) dAb fragments consisting of a VH domain (Ward et al., (1989) Nature 341: 544-546); (vi) separated complementarity-determining regions (CDRs); and (vii) nanobodies, heavy-chain variable regions containing a single variable domain and two constant domains. Furthermore, although the two domains VL and VH of the Fv fragment are encoded by separate genes, they can be linked together via adapters using recombination methods, thus forming a single protein chain in which the VL and VH regions pair to form a monovalent molecule (called a single-chain Fv (scFv); see, for example, Bird et al., (1988) Science 242:423-426; and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single-chain antibodies are also included within the scope of the term "antigen-binding fragment" in the term antibody. These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and the fragment screening performed for use is the same as that for intact antibodies.
[0179] As used herein, the term "monoclonal antibody" refers to a formulation of an antibody molecule having a single molecular composition. Monoclonal antibody compositions exhibit single binding specificity and affinity for a specific epitope.
[0180] The term "mouse antibody" refers to a monoclonal antibody against human GIPR prepared in accordance with the knowledge and skills of the art. Preparation can be performed by injecting a test subject (e.g., a mouse) with a GIPR antigen, followed by isolating a hybridoma expressing an antibody with the desired sequence or functional characteristics. The aforementioned mouse anti-GIPR antibody or its antigen-binding fragment may further include a light chain constant region of a mouse κ, λ chain, or a variant thereof, or further include a heavy chain constant region of mouse IgG1, IgG2, IgG3, or a variant thereof.
[0181] The term "chimeric antibody" refers to an antibody formed by fusing the variable region of a heterologous (e.g., murine) antibody with the constant region of a parental antibody (e.g., human antibody). Chimeric antibodies can mitigate the immune response induced by heterologous antibodies. For example, to create a human-mouse chimeric antibody, a hybridoma that secretes murine-specific monoclonal antibodies must first be established. Then, the variable region gene is cloned from the murine hybridoma cells. Next, the constant region gene of the human antibody is cloned as needed. The murine variable region gene and the human constant region gene are then linked to form a chimeric gene, which is inserted into an expression vector. Finally, the chimeric antibody molecule is expressed in a eukaryotic or prokaryotic system.
[0182] The term "humanized antibody," also known as a CDR-grafted antibody, refers to an antibody generated by grafting a mouse CDR sequence into the variable region framework of a human antibody, i.e., a different type of human germline antibody framework sequence. This overcomes the heterologous response induced by chimeric antibodies carrying a large amount of mouse protein components. Such framework sequences can be obtained from public DNA databases containing germline antibody gene sequences or from publicly available references. For example, germline DNA sequences of human heavy and light chain variable region genes are available in the VBase human germline sequence database and in Kabat, E.A. et al., 1991, Sequences of Proteins of Immunological Interest, 5th edition. To avoid a decrease in activity along with a decrease in immunogenicity, minimal reverse or reversion mutations can be performed on the aforementioned human antibody variable region framework sequence to maintain activity.
[0183] The terms "fully human antibody" and "fully human antibody" are used interchangeably, generally referring to antibodies whose entire composition (including the variable and constant regions) is encoded by genes of human origin. Fully human antibodies can significantly reduce the immune side effects caused by heterologous antibody components. Methods for obtaining fully human antibodies in this field include phage display technology, transgenic mouse technology, and ribosome display technology.
[0184] The term "variants" of the heavy chain constant region and light chain constant region refers to human variants of the heavy chain constant region or light chain constant region that do not alter the structure and function of the antibody variable region, as disclosed in the prior art. Exemplary variants include IgG1, IgG2, IgG3, or IgG4 heavy chain constant region variants that involve site-specific modifications and amino acid substitutions in the heavy chain constant region. Specific substitutions include YTE mutations, L234A and / or L235A mutations, S228P mutations, and / or mutations that acquire a knock-in-hole structure (resulting in a knock-Fc and hole-Fc combination in the antibody heavy chain). These mutations have been shown to impart novel properties to the antibody without altering the function of the antibody variable region.
[0185] The term "mutation" in the context of amino acids encompasses substitutions (replacements, substitutions), deletions, insertions, and modifications of amino acids. Any combination of substitutions, deletions, insertions, and modifications can be performed to obtain the final construct, provided that the final construct possesses the desired characteristics. Amino acid mutations can be generated using any genetic engineering or chemical method well known in the art, such as site-directed mutagenesis, PCR, gene synthesis, chemical modification altering amino acid side chain groups, etc. Various names may be used herein to indicate amino acid mutations; for example, the substitution of proline at position 329 of the Fc region with glycine is denoted as P329G.
[0186] The term "affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise stated, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of molecule X for its partner Y is typically expressed by the dissociation constant (KD). Affinity can be measured using conventional methods known in the art, including those described herein.
[0187] The term "isotype" refers to an antibody class (e.g., IgM or IgG1) encoded by a gene in the heavy chain constant region.
[0188] As used herein, the terms “comprising,” “including,” and “having” are used interchangeably to indicate the inclusiveness of a scheme, meaning that the scheme may contain elements other than those listed. It should also be understood that the use of “comprising,” “including,” and “having” in this document also provides for schemes “consisting of…”.
[0189] The terms “about” and “approximately” mean within 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of a given value or range.
[0190] The term "antibody" in this article includes, but is not limited to, monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), monovalent antibodies, multivalent antibodies, intact antibodies, antigen-binding fragments, naked antibodies, conjugated antibodies, humanized antibodies, or fully human antibodies.
[0191] The term "conservative amino acid" in this document generally refers to amino acids that belong to the same class or have similar characteristics (e.g., charge, side chain size, hydrophobicity, hydrophilicity, main chain conformation, and rigidity). For example, the amino acids in each of the following groups belong to each other's conserved amino acid residues, and substitutions of amino acid residues within a group constitute substitutions of conserved amino acids:
[0192] 1) Alanine (A), Serine (S), Threonine (T);
[0193] 2) Aspartic acid (D), glutamic acid (E);
[0194] 3) Asparagine (N), glutamine (Q);
[0195] 4) Arginine (R), Lysine (K), Histidine (H);
[0196] 5) Isoleucine (I), leucine (L), methionine (M), valine (V); and
[0197] 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
[0198] The terms "identity" and "sequence consistency" used herein are interchangeable and are calculated as follows: To determine the percentage of "identity" between two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., vacancies may be introduced in one or both of the first and second amino acid sequences or nucleic acid sequences for optimal alignment, or non-homologous sequences may be discarded for comparison purposes). The amino acid residues or nucleotides at corresponding amino acid or nucleotide positions are then compared. The molecules are identical at that position when a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence.
[0199] The term "antagonist" refers to the inhibition of receptor signaling to suppress a biological response associated with receptor activation. Antagonistic antibodies are used in the broadest sense to include antibodies that partially or completely block, inhibit, or neutralize the biological activity of an epitope, peptide, or cell to which they specifically bind. Methods for identifying antagonistic antibodies may include contacting a peptide or cell to which a candidate antagonistic antibody specifically binds with the candidate antagonistic antibody and measuring detectable changes in one or more biological activities typically associated with the peptide or cell.
[0200] The term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, for example, non-human primates, rodents, rabbits, pigs, dogs, cats, chickens, amphibians, and reptiles, although mammals such as non-human primates and rodents are preferred.
[0201] "Effective amount" includes an amount sufficient to treat or prevent the symptoms or condition of a medical condition. Effective amount also means an amount sufficient to allow or facilitate diagnosis. Effective amount should be understood in the context of the condition being treated, where the actual effective amount can be readily identified by a person skilled in the art.
[0202] The term "packaging insert" refers to the instructions typically included in the commercial packaging of a therapeutic product, which contain information concerning the indications, usage, dosage, administration, combination therapy, contraindications, and / or warnings related to the use of the therapeutic product.
[0203] The antibodies of the present invention are monoclonal antibodies characterized structurally and chemically as described below and in the following examples. The amino acid sequence IDs of the heavy / light chain variable regions of exemplary antibodies are summarized in Table 1, the sequence IDs of the heavy / light chain constant regions are summarized in Table 2, and the full-length sequence IDs of the heavy / light chains are summarized in Table 3.
[0204] Table 1
[0205] Table 2
[0206] Table 3
[0207] The heavy chain variable region and light chain variable region (CDR) in Table 1 can be determined according to the definitions of Kabat, Chothia, IMGT, AbM, Contact, or combinations thereof. Table 4 provides the amino acid sequences (defined by IMGT and Kabat) of the heavy chain / light chain CDRs of exemplary anti-GIPR antibodies of the present invention. Antibodies having the same heavy chain and light chain CDR1, CDR2, and CDR3 regions as the anti-GIPR antibodies of the present invention are also within the scope of the present invention.
[0208] Table 4
[0209] Other features and advantages of the present invention will become apparent from the following detailed description and examples, and should not be construed as limiting. All references, Genbank entries, patents, and published patent applications cited throughout this application are expressly incorporated herein by reference. Attached Figure Description
[0210] Figures 1 to 3 show the ELISA results of Example 2, where IgG1 or Human IgG is an isotype IgG antibody used as a negative control.
[0211] Figures 4A to 4D and Figure 6B show the binding of anti-GIPR antibodies to GIPR at the cellular level in the FACS experiment, where Human IgG is an allotype IgG antibody used as a negative control.
[0212] Figures 5A to 5D and Figure 6A show the antagonism of GIPR antibodies at the cellular level, with Human IgG serving as a negative control of the allotype IgG antibody.
[0213] Figures 7A to 7C show the binding of SGIP-P35, SGIP-P37, and SGIP-H183 optimized antibodies to cellular-level hGIPR.
[0214] Figures 8A to 8C show the antagonistic effects of SGIP-P35, SGIP-P37, and SGIP-H183 optimized antibodies on cellular-level hGIPR.
[0215] Figure 9 shows the antagonistic effect of the antibody on mouse GIPR at the cellular level.
[0216] Figure 10 shows the antagonistic activity of SGIP-P35.JS against hGIPR at the cellular level.
[0217] Figures 11-16 show the in vivo efficacy results in mice. Figures 11-12 show the in vivo efficacy of Example 7.1. Figure 13 shows the in vivo efficacy of Example 7.2. Figures 14-16 show the in vivo efficacy of Example 7.3. In Figure 14, compared with Group G1, groups G2-G5 showed p < 0.001; compared with Group G4, G2 showed p < 0.01; compared with Group G3, G5 showed p < 0.001. In Figure 15, compared with Group G1, G4 and G5 showed p < 0.001. In Figure 16, compared with Group G1, groups G2-G4 showed p < 0.01; compared with Group G1, G5 showed p < 0.001; compared with Group G3, G5 showed p < 0.05.
[0218] The positive control (control-Ab) involved in each embodiment is Maridebart, which is an anti-GIPR antibody. It is prepared by autonomous cloning according to the sequence disclosed in WHO Drug Information, Volume 36, Number 4, 2022, Proposed INN: List 128, and can also be prepared according to the construct 2G10 LC1.006 in patent CN109715662B. Specific Implementation
[0219] Example 1: Preparation of anti-GIPR monoclonal antibody
[0220] Various antibody development methods were used to identify the anti-GIPR monoclonal antibodies disclosed herein. To generate a diverse portfolio of antibodies, mouse immunizations were performed, and a phage display antibody expression platform was also employed.
[0221] Preparation of murine anti-GIPR antibodies
[0222] Prepare 10 Balb / c mice (female, 6-8 weeks old, 18-20g) and divide them into Group 1 and Group 2 for immunization, with 5 mice in each group.
[0223] Group 1 used a plasmid expressing hGIPR and whole cells expressing hGIPR as immunogens (hGIPR is Genbank ID: NP_000155.1). The immunization protocol was as follows: 0.2 mL of blood was collected from each mouse before immunization. Then, the plasmid expressing hGIPR was transfected into the mice via electroporation at a dose of 50 μg / mouse. The mice were immunized four times, once every two weeks. On day 14 after the fourth immunization, whole cells expressing hGIPR were transfected at a dose of 5 × 10⁶ cells / mouse. 6 Mice were subcutaneously injected with a dose of hGIPR cells / mouse for the fifth immunization; on day 29 after the fifth immunization, one mouse was selected, and whole cells expressing hGIPR were injected at a dose of 5 × 10⁻⁶ cells / mouse. 6 Sprint immunization was performed at a dose of cells / animal. On day 7 after each immunization (except for sprint immunization), a 0.2 mL blood sample was collected from the animal.
[0224] Group 2 used Fc-hGIPR-ECD (a fusion protein containing the hGIPR extracellular domain and Fc) and hGIPR-His (a histidine-tagged hGIPR protein) as immunogens. The immunization protocol was as follows: Before immunization, 0.2 mL of blood was collected from each mouse. Fc-hGIPR-ECD was mixed with complete Freund's adjuvant and then subcutaneously injected at a dose of 50 μg / mouse. On days 6, 27, and 41 after the first immunization, hGIPR-His was mixed with incomplete Freund's adjuvant and subcutaneously injected at a dose of 25 μg / mouse for the second, third, and fourth immunizations, respectively. On day 8 after the fourth immunization, hGIPR-His was mixed with PBS and injected at a dose of 25 μg into one mouse for a sprint immunization. On day 14 after the second immunization and day 7 after the third immunization, 0.2 mL of blood samples were collected from the animals.
[0225] Serum was separated by centrifugation, and serum titers were detected by ELISA and FACS (refer to Example 2). Mice with satisfactory titers were selected. The spleen and bone marrow of the mice were removed, ground into a single-cell suspension, and plasma cells were enriched using CD138 magnetic beads. Antigen-specific plasma cells were sorted and subjected to NGS sequencing and bioinformatics analysis to obtain paired light and heavy chain base and amino acid sequences. The selected sequences were then expressed in a mammalian system (constructing a human IgG1 subtype), i.e., candidate antibodies were cloned, expressed, and purified using conventional gene cloning and recombinant expression methods.
[0226] Preparation of murine anti-GIPR antibodies
[0227] The antigen and adjuvant were mixed and administered via subcutaneous lymph node immunization to several C57BL / 6, BALB / c, and SJL mice using the Hock immunization program (the antigen contains the hGIPR extracellular domain (amino acid residues 26-138)). Blood was collected from the immunized animals, serum was separated, and serum titers against the target antigen were detected by ELISA and FACS. Mice with satisfactory titers were selected. SP2 / 0 cells and spleen cells from immunized mice were fused using electrofusion to obtain hybridoma cells. Positive hybridoma clones against the target antigen were screened using FACS and ELISA. Cell subcloning was performed using limiting dilution to obtain stable, single positive hybridoma cells, and then NGS sequencing was used to obtain the variable region sequence of the antibody. The selected murine heavy chain variable region and light chain variable region were linked to the heavy chain constant region and human κ light chain constant region of the human IgG1 antibody, respectively, to form chimeric antibodies. Antibodies were expressed using the ExpiCHO cell system. The supernatant was collected, purified with Protein A, and the purity of the antibodies was identified by SDS-PAGE. ELISA and FACS were then used for detection.
[0228] Preparation of fully human anti-GIPR antibodies
[0229] A fully human natural phage library was prepared, and positive enrichment was obtained by 2-3 rounds of panning targeting whole cells expressing hGIPR and hGIPR(22-138)-Fc. In summary, Method 1 involves cell panning. Whole cells expressing hGIPR are co-incubated with a phage library. After incubation, unbound phages are removed, and the bound phages are eluted with TEA. 1 ml of the neutralized phage product is added to 10 ml of TG1 bacterial culture in logarithmic growth phase, mixed thoroughly, and incubated at 37°C for 45 min. Method 2 involves solid-phase panning. hGIPR(22-138)-Fc is coated onto solid-phase strips and bound to a phage library. After capture, unbound phages are washed with PBS to remove them. The bound phages are then eluted with TEA, and 1 ml of the neutralized phage product is added to 10 ml of TG1 bacterial culture in logarithmic growth phase, mixed thoroughly, and incubated at 37°C for 45 min. Transfected cells are cultured, and the binding activity of the expression supernatant of the cultured monoclonal bacterial culture against the antigen is analyzed using ELISA and FACS (refer to Example 2) to screen for positive clones. The positive clones selected from schemes one and two were sequenced, and the corresponding expression plasmids were constructed, and antibodies were expressed and purified.
[0230] The amino acid sequence structure information of the candidate antibody prepared in this embodiment is shown in Table 5. The heavy chain variable region is directly linked to the human IgG1 heavy chain constant region to form the heavy chain of the full-length antibody, and the light chain variable region is directly linked to the human κ light chain constant region to form the light chain of the full-length antibody.
[0231] Table 5 Sequence structure of anti-GIPR antibodies
[0232] Example 2: Validation of anti-GIPR monoclonal antibody binding activity
[0233] ELISA experiment
[0234] The in vitro binding activity of the candidate antibody was verified by ELISA. The antigen protein used was the tagged hGIPR, which has a 6×His-Avi tag at the C-terminus (sequence HHHHHHGLNDIFEAQKIEWHE) and an N-terminal hGIPR sequence (Genbank ID: NP_000155.1, positions 23-138). The ELISA protocol is as follows:
[0235] (1) Coating of protein: 2 μg / mL of antigen protein was coated on ELISA strips, 100 μL / well, and incubated at 37℃ for 1 h. The strips were then washed 6 times and patted dry.
[0236] (2) Blocking: 200 μL of blocking solution per well, block at 25℃ for 1 h, then wash the plate 6 times and pat dry;
[0237] (3) Antibody binding: Add serially diluted antibodies to the wells. The first well contains 100 nM or 15 μg / mL of the antibody to be tested. Dilute it 3 times with blocking buffer in 11 gradients. The last well is blank. 100 μL / well. Incubate at 25℃ for 1 h. Then wash the plate 6 times and pat dry.
[0238] (4) Binding of secondary antibody: Add HRP-labeled human IgG secondary antibody, i.e., Anti-human Fc specific HRP diluted 1:10000 with blocking buffer, or Anti-Human IgG (Fab specific) HRP diluted 1:50000 with blocking buffer, 100 μL / well, incubate at 25℃ for 1 h, then wash the plate 6 times and pat dry;
[0239] (5) Color development: 100 μL / well color development solution, develop color at room temperature in the dark for 3-5 min;
[0240] (6) Termination: 50 μL / well stop solution;
[0241] (7) Reading: OD was read using an enzyme-linked immunosorbent assay (ELISA) reader. 450 .
[0242] Fortebio Experiment
[0243] The affinity constant (KD) of hGIPR to candidate antibodies was determined by kinetic analysis. The Fortebio protocol was as follows: biotinylated hGIPR (26-138) protein was diluted to 1200 nM, followed by 2-fold serial dilutions to prepare seven concentration gradients. The antibody to be tested was immobilized onto a Protein A sensor for 60 s, equilibrated in buffer for 60 s, and then bound to each concentration gradient of hGIPR protein for 150 s. The antigen and antibody were dissociated in buffer for 180 s. The Protein A sensor was then regenerated at pH 1.5. After multiple cycles of detection, the data were fitted and analyzed to obtain the affinity constant (KD), binding rate constant (Kon), and dissociation rate constant (Kdis) of the antibody to hGIPR. The experimental results showed that the KD values of the candidate antibodies shown in Table 5 were all below 10. -7 M indicates that the antibody of this invention has a strong binding ability to human GIPR.
[0244] FACS Experiment
[0245] The binding affinity of the candidate antibody to the hGIPR-expressing cell line (HEK293 / CRE-LUC / GIPR, purchased from GenScript) was detected by FACS. The results are shown in Figures 4 and 6B. The FACS protocol is as follows:
[0246] (1) Adjust the cell density to 3×10⁻⁶ 6 Add 50 μL per well to a 96-well plate at a concentration of cells / mL;
[0247] (2) Dilute the antibody to be tested 3- or 4-fold serially with MACS Buffer, with the first well having a final concentration of 100 nM and the last well a blank. Add 50 μL of the solution to the cell wells of a 96-well plate.
[0248] L / well, incubate at 4℃ for 1 hour;
[0249] (3) Centrifuge at 400g and 4℃ for 5min, discard the supernatant, and wash twice with 150μL of MACS Buffer;
[0250] (4) Add 100 μL of diluted Alexa Fluor Labeled goat anti-human IgG fluorescent secondary antibody, incubated at 4℃ for 30 min;
[0251] (5) Centrifuge at 400g and 4℃ for 5min, discard the supernatant, and wash twice with 150μL of MACS Buffer;
[0252] (6) After resuspending in 100 μL MACS Buffer, the cells were analyzed by flow cytometry.
[0253] Further comparisons were made between the binding of some antibodies and positive controls (Control-Ab) to hGIPR at the cellular level, and the results are shown in Table 6. It can be seen that the antibodies of the present invention have better binding activity.
[0254] Table 6
[0255] ELISA, Fortebio, and FACS experiments verified that the present invention screened several positive anti-GIPR antibodies, which in particular showed good binding activity to extracellular hGIPR.
[0256] Example 3: Verification of the antagonistic activity of anti-GIPR monoclonal antibody at the cellular level
[0257] The antagonistic effect of anti-GIPR antibodies on GIPR in vitro was detected using reporter gene assays. The HEK293 / CRE-LUC / GIPR cell line stably expresses the human GIPR gene and, under the regulation of the cAMP response element (CRE), expresses the firefly luciferase gene. In the absence of a GIPR agonist (e.g., GIP), GIPR in these cells is not activated, resulting in low luminescence signal. However, in the presence of the agonist, a dose-dependent fluorescence signal indicating GIPR pathway activation can be detected. Therefore, monitoring the fluorescence signal of the HEK293 / CRE-LUC / GIPR cell line can reflect whether anti-GIPR antibodies block the interaction between GIP and GIPR. The specific experimental protocol is as follows:
[0258] (1) Adjust the density of HEK293 / CRE-LUC / GIPR cells to 2×10⁻⁶ using DMEM medium containing 10% FBS. 5 cells / mL, then 100 μL / well was seeded into a 96-well plate (2 × 10⁻⁶ cells / mL). 4 cells / well) and cultured overnight in a CO2 incubator at 37°C;
[0259] (2) Dilute the antibody to be tested three times with FBS-free DMEM medium, with the first well concentration being 100 nM, 150 nM or 378 nM. Dilute the GIP with DMEM medium to 2 nM.
[0260] (3) Take out the 96-well plate, remove the cell supernatant, add the diluted antibody, 50 μL / well, and incubate at 37°C and 5% CO2 for 1 h. Then add 50 μL / well of GIP and incubate at 37°C and 5% CO2 for 6 h.
[0261] (4) Remove the 96-well plate from the incubator, equilibrate at room temperature for 15 min, add 100 μL of Bio-Lite reagent per well, shake to mix and incubate at room temperature for 3 min;
[0262] (5) Use a plate reader to measure luciferase activity and plot the fitting curve.
[0263] The reporter gene experiment is shown in Figures 5 and 6A, which shows that the anti-GIPR antibody of the present invention has an antagonistic effect on the GIP receptor at the cellular level.
[0264] Example 4: Modification, Optimization, and Activity Evaluation of Candidate Antibodies
[0265] The variable region sequence of murine antibodies (e.g., SGIP-H183) was modified using the CDR transplantation method to generate corresponding humanized antibodies. In short, the amino acid sequences of the VH and VL regions of the murine antibody (e.g., SGIP-H183) were compared with available human Ig gene sequence databases to find the best-matching human germline Ig gene sequence overall, and different numbers of reversion mutations were introduced into the selected human framework to maintain the structure and / or function of the resulting antibody. Furthermore, the humanized antibody (e.g., a humanized version of SGIP-H183) and fully human antibodies (e.g., SGIP-P35, SGIP-P37) were modified to obtain the VH and VL sequences shown in Tables 7 and 8 (the underlined amino acid residues indicate the CDR region defined by Kabat).
[0266] Table 7
[0267] Table 8
[0268] The VH sequences shown in Table 7 and the VL sequences shown in Table 8 were combined to create optimized humanized and fully human antibodies. The variable region sequences of each antibody are shown in Table 9. The required constant regions for the antibodies are derived from human IgG1. The complete sequences of each antibody can be obtained by directly splicing the constant region sequences with the VH and VL sequences shown in Table 9. The DNA coding sequences of the antibody variable regions shown in Table 9 were synthesized. The DNA of VH was inserted into a mammalian cell expression vector containing the gene encoding the heavy chain constant region shown in SEQ ID NO. 66, and the DNA of VL was inserted into a mammalian cell expression vector containing the gene encoding the light chain constant region shown in SEQ ID NO. 67. These were co-transfected into mammalian cells capable of expressing the aforementioned vectors. After culturing for several days, the cell supernatant was collected and purified to harvest the antibodies (purity > 95%).
[0269] Table 9
[0270] Following the Fortebio experimental protocol described in Example 2, the affinity of the antibody in this example for hGIPR was tested. The results showed that the KD values of all antibodies were below 10. -7 M, the optimized antibody has an affinity that is no less than that of its parent antibody or is 1-3 orders of magnitude higher (10) than that of the parent antibody. -8 M to 10 -10 M). Further comparisons were made between the affinity of some antibodies and positive controls (Control-Ab) for hGIPR, and the results are shown in Tables 10.1-10.4. It can be seen that most of the antibodies of the present invention have better affinity for human GIPR protein.
[0271] Table 10.1
[0272] Table 10.2
[0273] Table 10.3
[0274] Table 10.4
[0275] Following the FACS experimental protocol described in Example 2 (antibody 50 or 100 nM, 4-fold serial dilution), the binding activity of the antibody in this example with extracellular hGIPR was tested, and the results are shown in Figures 7A to 7C. Figure 7A shows the binding of the SGIP-P35 optimized antibody with cellular hGIPR, Figure 7B shows the binding of the SGIP-P37 optimized antibody with cellular hGIPR, and Figure 7C shows the binding of the SGIP-H183 optimized antibody with cellular hGIPR. Figures 7A to 7C show the ECG binding of the optimized antibody of this example with hGIPR. 50 Less than 5 nM, with binding activity comparable to or better than that of the parent antibody.
[0276] Following the reporter gene assay protocol described in Example 3 (antibody 200 or 300 nM, 3-fold serial dilution), the antagonistic activity of the antibody in this example against the GIP receptor at the cellular level was tested, and the results are shown in Figures 8A to 8C. Figure 8A shows the antagonistic effect of the SGIP-P35 optimized antibody against hGIPR at the cellular level, Figure 8B shows the antagonistic effect of the SGIP-P37 optimized antibody against hGIPR at the cellular level, and Figure 8C shows the antagonistic effect of the SGIP-H183 optimized antibody against hGIPR at the cellular level. Figures 8A to 8C show the IC50 of the optimized antibody in this example against hGIPR. 50 Less than 20 nM, exhibiting antagonistic activity comparable to or better than the parental antibody. Further comparisons were made of the antagonistic abilities of some antibodies against hGIPR at the cellular level between individual antibodies and between some antibodies and the positive control (Control-Ab). The results are shown in Tables 11.1-11.6. It is evident that most antibodies of the present invention can better antagonize human GIPR protein, especially most SGIP-P35 optimized antibodies such as SGIP-P35.I, SGIP-P35.J, SGIP-P35.F, SGIP-P35.G, and SGIP-P35.H, which exhibit better antagonistic activity than the positive control.
[0277] Table 11.1
[0278] Table 11.2
[0279] Table 11.3
[0280] Table 11.4
[0281] Table 11.5
[0282] Table 11.6
[0283] Example 5: Genera Cross-Reactivity Test
[0284] Furthermore, referring to the FACS experimental protocol described in Example 2, the cross-reactivity of some antibodies with mouse GIPR (mGIPR) and cynomolgus monkey GIPR at the cellular level was tested. The results showed that the antibodies exhibiting better mGIPR binding activity included: SGIP-P35, SGIP-P35.A, SGIP-P35.B, SGIP-P35.C, SGIP-P35.D, SGIP-P35.I, SGIP-P35.J, and SGIP-P35.G; SGIP-P37, SGIP-P37.B, SGIP-P37.C, SGIP-P37.D, SGIP-P37.E, SGIP-P37.F, SGIP-P37.G, and SGIP-P37.H; and SGIP-H183, SGIP-H183.A, SGIP-H183.B, SGIP-H183.C, SGIP-H183.D, SGIP-H183.E, and SGIP-H183.G. Antibodies exhibiting superior cynoGIPR binding activity include SGIP-P35.G, SGIP-P35.J, SGIP-P37.H, and SGIP-H183.G.
[0285] The study tested whether certain antibodies and a positive control (Control-Ab) could antagonize mouse GIPR at the cellular level. First, a cell line stably expressing mGIPR was constructed. The mGIPR gene was cloned into an expression vector, which was then transfected into CHO-K1 cells. After antibiotic selection, single clones were selected, and positive clones were amplified and cultured to obtain a stable mouse GIPR-expressing cell line, named the CHO-K1 / mGIPR cell line. The CHO-K1 / mGIPR cell line stably expresses mouse GIPR protein. In the presence of an mGIPR agonist (such as mouse GIP (mGIP)), it activates adenylate cyclase through G protein signaling systems. Under the action of adenylate cyclase, ATP loses one pyrophosphate phosphate to generate cAMP. Therefore, monitoring the cAMP concentration signal in cells can reflect whether the anti-GIPR antibody blocks the interaction between mGIP and mGIPR. The cAMP concentration signal was measured using a cAMP kit (Revvity, catalog number 62AM4PEB).
[0286] The specific experimental protocol is as follows: (1) Adjust the CHO-K1 / mGIPR cell density to 4×10 5 (1) Seed 5 μL / well into a 384-well plate and culture; (2) Dilute each sample to the initial working concentration and then serially dilute to several concentration gradients; (3) Add 1 μL of the sample diluent at each concentration gradient to each cell culture well, and set blank control wells and negative control wells. After sealing the plate, incubate it in a 37℃, 5% CO2 incubator for 10 min; (4) Then add 4 μL of mGIPR agonist to each cell culture well. After sealing the plate, incubate it in a 37℃, 5% CO2 incubator for 30 min; (5) Take out the 5×cAMP EU Cryptate antibody and 5×cAMP d2 reagent from the kit and dilute them to 1× according to the instructions. Add 4.3 μL of 1×cAMP d2 reagent and 4.3 μL of 1×cAMP EU Cryptate antibody to each cell culture well. After sealing the plate, place it at room temperature for 1 h; (6) PHERAstar FSX multi-functional microplate reader, 665nm and 620nm, readings; (7) Inhibition Ratio=(Sample-Ave_H) / (Ave_H-Ave_L)×100, curve fitting was performed after GraphPad Prism processing, and the EC50 value was calculated. All the above tests were performed in duplicate. The results are shown in Figure 9. It can be seen that the antibody of the present invention also has a better antagonistic effect on mouse GIPR protein expressed by cells than the positive control antibody.
[0287] Example 6
[0288] To verify whether the previously constructed long-acting antibody has improved FcRn binding affinity, DNA of VH as shown in SEQ ID NO.48 was inserted into a mammalian cell expression vector containing the heavy chain constant region encoding gene as shown in SEQ ID NO.68, and DNA of VL as shown in SEQ ID NO.61 was inserted into a mammalian cell expression vector containing the light chain constant region encoding gene as shown in SEQ ID NO.67. Cell co-transfection, culture, expression, and purification were performed to construct the non-long-acting control antibody SGIP-P35.JS.
[0289] The affinity of human FcRn for two antibodies was detected using ForteBio. Biotinylated human FcRn receptor protein was diluted to 2.5 μg / ml with diluent (0.05% PBST, pH = 6.0) as a solidified protein. The biotinylated FcRn receptor protein was solidified using an SA sensor to a height of 1.0 nm. The test antibodies were diluted to 100 nM with diluent, and then serially diluted 2-fold to prepare seven concentration points. The SA sensor was equilibrated in the diluent for 60 s, and then the solidified FcRn sensor was bound to the test antibodies at each concentration gradient for 60 s. FcRn and antibodies dissociated in the diluent for 180 s. The SA sensor was regenerated in regeneration buffer (0.05% PBST, pH = 7.4) and neutralized in the diluent. After multiple cycles of "equilibrium, binding, dissociation, regeneration, and neutralization" testing, the data were fitted and analyzed to obtain the affinity constant (KD), binding rate constant (Kon), and dissociation rate constant (Kdis) between the test antibody and the FcRn receptor protein. The results confirmed that SGIP-P35.J carrying the LS mutation had an approximately 10-fold increased affinity for FcRn (Table 12). In addition, the antagonistic activity of SGIP-P35.JS against hGIPR at the cellular level was tested, showing that the long-term modification of the Fc region does not significantly change the function of the antibody's variable region (Figure 10).
[0290] Table 12
[0291] Example 7: In vivo efficacy study
[0292] 7.1 Pharmacodynamic Study 1
[0293] DIO mice (50-51g) induced with HFD (D12492) for 21 weeks were randomly divided into groups according to body weight. The day of group administration was designated as D0 (day 0). Following the grouping information, dosage, and frequency shown in Table 13, mice were subcutaneously injected with PBS (group A), semaglutide (group B), SGIP-P35.J (group C), and semaglutide + SGIP-P35.J (groups D1 and D2) several times. In groups B and D1, drug administration was discontinued on D24, while in group D2, only semaglutide administration was discontinued on D24. Body weight, food intake, and blood glucose data were collected during the experimental period. After the experiment (D57), the mice were euthanized, and their livers were dissected, weighed, fixed in 4% neutral formaldehyde solution, embedded in paraffin, and sectioned. The results showed that compared with group A, groups B, C, D1 and D2 all reduced mouse body weight, liver weight and blood glucose to varying degrees. The results of body weight and liver weight are shown in Figures 11-12. The data are expressed as mean ± standard deviation (Mean ± SD) and were tested using T-TEST.
[0294] Table 13 Note: "D0~24: q3d" means that the drug is administered once every 3 days during the treatment period from day 0 to day 24; "D24~49: qw" means that the drug is administered once a week during the treatment period from day 24 to day 49.
[0295] These data indicate that the anti-GIPR antibody of this invention alone can produce a weight loss effect, particularly effectively reducing liver weight in obese mice and maintaining body weight well compared to group A. Further combination with a GLP-1 agonist showed an enhanced weight loss effect. Compared to the rapid weight rebound after discontinuation of GLP-1 agonist alone (group B), group D1, although both drugs were discontinued simultaneously, still exhibited a certain inhibitory effect on weight rebound in the early stages after drug withdrawal due to the extended half-life of the GIPR antibody after its long-acting modification. Group D2, with continued administration of the GIPR antibody after discontinuation of the GLP-1 agonist, further highlighted the role of the GIPR antibody in inhibiting rapid weight rebound and was also more effective in reducing liver weight and improving liver metabolic status.
[0296] 7.2 Pharmacodynamics Study 2
[0297] DIO mice (50–52 g) induced by HFD (D12492) for 20 weeks were randomly divided into groups according to their body weight. The day of group administration was designated D0 (day 0). Following the grouping information, dosage, and frequency shown in Table 14, mice were subcutaneously injected with PBS (group A), semaglutide (group B), semaglutide, and SGIP-P35.J (group C) several times. Groups B and C received only semaglutide from D0 to D21. After the last semaglutide administration on D21, group C received weekly subcutaneous injections of SGIP-P35.J starting on D21 until D52. Mouse body weight was collected during the experimental period. The results showed that group C significantly alleviated the weight rebound effect compared to group B. Results are shown in Figure 13 (**P < 0.01). Data are expressed as mean ± standard deviation (Mean ± SD) and were analyzed using the T-test.
[0298] Table 14
[0299] 7.3 Pharmacodynamics Study 3
[0300] This embodiment aims to evaluate the pharmacological effects of GIPR antibody and GLP-1 / GCG dual receptor agonist in diet-induced obese (DIO) mice. Evaluation indicators included: body weight, food intake, animal body composition (lean meat weight, fat weight), fasting blood glucose, and serum biochemistry (alanine aminotransferase (ALT), aspartate aminotransferase (AST)).
[0301] Methods: Male C57BL / 6J mice aged 21–23 weeks were used, including lean control mice (basal diet) or mice induced to become obese for 16–18 weeks on a 60% high-fat diet (D12492, Research diets). DIO mice were randomly divided into several groups (groups G1–G5, 6–12 mice / group) according to their baseline body weight. Subcutaneous drug administration began on day 0. The study groups are as follows:
[0302] Table 15
[0303] Note: q3d means dosing once every 3 days; qw means dosing once a week; sc means subcutaneous administration.
[0304] Mouse body weight changes were monitored during the study. At the experimental endpoint (day 15), fasting blood glucose levels were measured, and mouse serum was collected for blood biochemistry analysis (ALT) using a fully automated biochemical analyzer (TBA-1500FR, Canon Medical Systems Co., Ltd.).
[0305] Data analysis was performed using Graphpad Prism statistical software. First, the data were tested for normality and homogeneity of variance. For data conforming to normality (P>0.05) and homogeneity of variance (P>0.05): one-way ANOVA with Dunnett's multiple comparison test was used for comparisons among multiple groups, with P<0.05 considered statistically significant. If variances were unequal (P<0.05), Brown-Forsythe and Welch ANOVA tests were used. If the data did not conform to normality: the Kruskal-Wallis H nonparametric test was used for multiple comparisons among multiple groups, with P<0.05 considered statistically significant.
[0306] The results are shown in Figures 14-16, which sequentially display the changes in body weight, fasting blood glucose, and blood biochemistry for each group. It is evident that the anti-GIPR antibody of this disclosure, when used in combination with a GLP-1 receptor agonist or a GLP-1 / GCG dual receptor agonist, exhibits a synergistic effect, reducing body weight more effectively than with monotherapy. Furthermore, compared to the combination with semaglutide, the combination of the anti-GIPR antibody of this invention with Survodutide shows a better synergistic trend; the differences in body weight reduction and improvement in liver function (ALT) are more significant in groups G5 and G3 than in groups G4 and G2.
[0307] Although the invention has been described through one or more embodiments, it should be understood that the invention is not limited to these embodiments, and the specification is intended to cover all alternatives, modifications, and variations falling within the spirit and broad scope of the appended claims. All references cited in this invention are incorporated herein by reference in their entirety.
Claims
1. A pharmaceutical composition, characterized by, The pharmaceutical composition comprises: (a) an anti-GIPR antibody or its antigen-binding fragment; and, (b) A GLP-1 / GCG dual receptor agonist or a pharmaceutically acceptable salt thereof, or a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition of claim 1, wherein, The anti-GIPR antibody or its antigen-binding fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises HCDR1, HCDR2, and HCDR3 regions, and the VL comprises LCDR1, LCDR2, and LCDR3 regions, wherein: (1) The HCDR1, HCDR2, and HCDR3 regions have sequences identical to those of the HCDR1, HCDR2, and HCDR3 of any VH shown in SEQ ID NO: 1, 3, 5, or 7, or sequences with at most 5, 4, 3, 2, or 1 mutations compared to each CDR in HCDR1-3 of any VH shown in SEQ ID NO: 1, 3, 5, or 7; and, the LCDR1, LCDR2, and LCDR3 regions have sequences identical to those of the LCDR1, LCDR2, and LCDR3 of any VL shown in SEQ ID NO: 2, 4, 6, or 8, or sequences with at most 5, 4, 3, 2, or 1 mutations compared to each CDR in LCDR1-3 of any VL shown in SEQ ID NO: 2, 4, 6, or 8; or, (2) The HCDR1, HCDR2, and HCDR3 regions have sequences identical to those of the HCDR1, HCDR2, and HCDR3 of any VH shown in SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, or sequences that have undergone at most 5, 4, 3, 2, or 1 mutation compared to each CDR in HCDR1-3 of any VH shown in SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31; and the LCDR1, LCDR2, and LCDR3 regions have sequences identical to those of the LCDR1, LCDR2, and LCDR3 of any VL shown in SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or sequences that have undergone at most 5, 4, 3, 2, or 1 mutation compared to each CDR in HCDR1-3 of any VH shown in SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31; and sequences that have undergone at most 5, 4, 3, 2, or 1 mutation compared to each CDR in HCDR1-3 of any VH shown in SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31. NO: The sequence with up to 5, 4, 3, 2 or 1 mutations compared to each CDR in LCDR1-3 of any of the VLs shown in NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32; The mutations are selected from insertions, deletions and / or substitutions that do not affect function, and the substitutions are preferably substitutions of conserved amino acids; Alternatively, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 33, 34, 35 and 36, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO:
56. Alternatively, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 34, 37 and 38, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO:
57. Alternatively, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 39, 40, 41, 42 and 43, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO:
58. Alternatively, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in SEQ ID NO: 44, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO:
59. Alternatively, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in SEQ ID NO: 45, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO:
60. Alternatively, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in any of SEQ ID NO: 46, 47 and 48, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO:
61. Alternatively, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as any of the VHs shown in SEQ ID NO: 49-55, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO:
62. Alternatively, the VH has the same sequence of HCDR1, HCDR2 and HCDR3 as the VH shown in SEQ ID NO: 53, and the VL has the same sequence of LCDR1, LCDR2 and LCDR3 as the VL shown in SEQ ID NO:
63. And / or, the HCDR1, HCDR2 and HCDR3 of the VH, and the LCDR1, LCDR2 and LCDR3 of the VL are defined according to IMGT, Kabat, Chothia, AbM, Contact or any combination thereof.
3. The pharmaceutical composition of claim 2, wherein, The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 1, 3, 5, 7, 39-55, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 2, 4, 6, 8, 58-63; The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 31, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 32; The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 33, 34, 35, or 36, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 56; The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 34, 37, or 38, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 57; The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 39, 40, 41, 42, 43, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 58; The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 44, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 59; The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 45, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 60; The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 46, 47, or 48, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 61; The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any of SEQ ID NO: 49-55, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 62; or The VH has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 53, and / or the VL has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO:
63.
4. The pharmaceutical composition according to any one of claims 1 to 3, characterized in that, The anti-GIPR antibody or its antigen-binding fragment further comprises a heavy chain constant region and a light chain constant region.
5. The pharmaceutical composition according to any one of claims 1 to 4, characterized in that, The anti-GIPR antibody or its antigen-binding fragment comprises a heavy chain and a light chain, wherein the heavy chain has an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 98%, 99%, 100%, 101%, 102%, 103%, 105%, 107%, 109, 110, 111, or 112 identical to the sequence shown in SEQ ID NO: 75, 77, 79, 81, 83, 85, 87, 89, 90, 91, 92, 93, 109, 110, 111, or 112, and / or the light chain has an amino acid sequence that is identical to the sequence shown in SEQ ID NO: 75, 77, 79, 81, 83, 85, 87, 89, 90, 91, 92, 93, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, ...100%, and / or the light chain has an amino acid sequence that is identical to the sequence shown in SEQ ID NO: 75, 77, 79, 81, NO: The amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any of the sequences shown in NO: 76, 78, 80, 82, 84, 86, 88, 97, 104, 106, 108; And / or, the heavy chain and light chain respectively have at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a combination of heavy chains and light chains selected from the following group: (1) The heavy chain shown in SEQ ID NO: 75 and / or the light chain shown in SEQ ID NO: 76; (2) The heavy chain shown in SEQ ID NO: 77 and / or the light chain shown in SEQ ID NO: 78; (3) The heavy chain shown in SEQ ID NO: 79 and / or the light chain shown in SEQ ID NO: 80; (4) The heavy chain shown in any of SEQ ID NO: 81, 89, 90, 91, 92 and / or the light chain shown in SEQ ID NO: 82; (5) The heavy chain shown in SEQ ID NO: 83 and / or the light chain shown in SEQ ID NO: 84; (6) The heavy chain shown in SEQ ID NO: 85 and / or the light chain shown in SEQ ID NO: 86; (7) The heavy chain shown in any of SEQ ID NO: 87, 93, 94, 95 and / or the light chain shown in SEQ ID NO: 88; (8) The heavy chain shown in any of SEQ ID NO: 96, 98, 99, 100, 101, 102, 103 and / or the light chain shown in SEQ ID NO: 97; (9) The heavy chain shown in SEQ ID NO: 101 and / or the light chain shown in SEQ ID NO: 104; (10) The heavy chain shown in any of SEQ ID NO: 105, 107, 109, 110 and / or the light chain shown in SEQ ID NO: 106; or (11) The heavy chain shown in any of SEQ ID NO: 107, 111, 112 and / or the light chain shown in SEQ ID NO:
108.
6. The pharmaceutical composition according to any one of claims 1 to 5, characterized in that, The anti-GIPR antibody or its antigen-binding fragment has at least one of the following functions: (1) When binding to human GIPR, the antibody or its antigen-binding fragment has a KD of less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 1 nM or lower; (2) When bound to human GIPR, the KD of the antibody or its antigen-binding fragment is substantially the same as or better than that of the reference GIPR antibody; (3) When binding to human GIPR, the antibody or its antigen-binding fragment inhibits or blocks GIP signaling; or (4) When inhibiting or blocking the GIP activation of human GIPR, the inhibitory or blocking effect of the antibody or its antigen-binding fragment is basically the same as or better than that of the reference GIPR antibody. And / or, the anti-GIPR antibody or its antigen-binding fragment is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody; And / or, the antigen-binding fragment is selected from: Fab, F(ab')2, Fab', Fd, Fv, dsFv, scFv and biantibodies.
7. The pharmaceutical composition according to any one of claims 1-6, characterized in that, The GLP-1 / GCG dual receptor agonist is selected from gastrin (OXM) or its analogues, glucagon or its analogues; or, The GLP-1 receptor agonist is selected from GLP-1 (7-37) or its analogues; And / or, the GLP-1 / GCG dual receptor agonist is selected from Survodutide; And / or, the GLP-1 receptor agonist is selected from Semaglutide.
8. A reagent kit or medicine box comprising: (a) the anti-GIPR antibody or its antigen-binding fragment according to any one of claims 2-6; and (b) A GLP-1 / GCG dual receptor agonist or a pharmaceutically acceptable salt thereof, or a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof.
9. A method for preventing, alleviating and / or treating obesity or obesity-related diseases or conditions in a subject, comprising co-administering to a subject in need (a) an anti-GIPR antibody or an antigen-binding fragment thereof as described in any one of claims 2-6 and (b) a GLP-1 / GCG dual receptor agonist or a pharmaceutically acceptable salt thereof or a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof.
10. (a) The use of the anti-GIPR antibody or antigen-binding fragment thereof according to any one of claims 2-6 in combination with (b) a GLP-1 / GCG dual receptor agonist or a pharmaceutically acceptable salt thereof, or a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof, in the preparation of a medicament, a pharmaceutical composition, a kit or cassette; The drug, pharmaceutical composition, kit, or cassette is intended to prevent, alleviate, and / or treat obesity or obesity-related diseases or conditions in a subject; and / or, The drug, pharmaceutical composition, kit, or cassette is used for weight management or weight loss; and / or, The drug, pharmaceutical composition, kit, or cassette is used to improve liver function, reduce liver weight, or regulate blood sugar.
